# Semaglutide

Semaglutide has 610 registered human trials. It is marketed for 3 different uses.

**In short**

- 610 registered human trials exist for Semaglutide.
- Semaglutide is FDA-approved — FDA-approved for type 2 diabetes and chronic weight management..
- What has actually been studied: diabetes, diabetes mellitus, type 2, diabetes mellitus.
- Last checked against ClinicalTrials.gov on 2026-07-27.

## What it is sold for

- Weight loss
- Blood sugar control
- Cardiovascular risk

## What has actually been tested

- Diabetes
- Diabetes Mellitus, Type 2
- Diabetes Mellitus
- GLP - 1
- Obesity & Overweight
- Muscle Loss
- Exercise Intervention
- Dietary Assessment
- Nonalcoholic Steatohepatitis
- Type 2 Diabetes
- Chronic Kidney Diseases
- Obesity
- Alcohol Abuse
- Alcohol Addiction
- Alcohol Dependence
- Alcohol Use Disorder
- Peripheral Arterial Disease
- Pediatric Obesity
- Metabolic and Bariatric Surgery
- Semaglutide
- HIV Infections
- Non-Alcoholic Fatty Liver Disease
- Glucagon-Like Peptide-1 Receptor Agonists
- Coronary Arterial Disease (CAD)
- Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
- Non-alcoholic Fatty Liver Disease
- Alcohol-related Liver Disease
- Mobility Disability
- HOMA-IR
- Metabolic Syndrome
- Adults With Simple Obesity
- Metabolic Associated Fatty Liver Disease
- Metabolic Associated-dysfunction Steatohepatitis (MASH)
- Type 2 Diabetes (T2DM)
- Kidney Transplant Recipient
- Type 2 Diabetes Mellitus (T2DM)
- Weight Loss Maintenance
- Overweight and Obesity
- Gastroparesis
- Healthy Volunteers Type 2 Diabetes
- Weight Gain
- Healthy Volunteers
- Obesity and Overweight
- Appetite Regulation
- Renal Impairment
- Inflammatory Bowel Diseases
- Opioid Use Disorder
- Opioid Abuse and Addiction
- Narcotic-Related Disorders
- Substance-Related Disorders
- Chemically-Induced Disorders
- Mental Disorder
- Opioid
- Prostate Cancer
- Type 1 Diabetes
- Infertility
- Overweight
- Stage 1 Diabetes Mellitus, Type 1
- Healthy
- Healthy Participants
- Obesity, Childhood
- Polycystic Ovary Syndrome (PCOS) Women
- Type 2 Diabetes With Renal Manifestations
- Dyspnea
- Quality of Life
- Diabetes type2
- OSA
- Stroke
- Stroke, Acute
- Stroke, Ischemic
- Brain Diseases
- Obesity or Overweight
- Liver Cirrhoses
- Portal Hypertension Related to Cirrhosis
- Severe Obesity
- TIPS
- Scleroderma, Systemic
- Fibrosis
- Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
- Weight Loss
- Weight Reduction
- Cardiometabolic Risk Factors
- Heart Failure
- Psoriasis Vulgaris
- Diabetes Type 2
- Weight Management
- Psoriasis (PsO)
- Diabetes Mellitus - Type 2
- Obesity (Disorder)
- Weight Change
- Blood Pressure Monitoring
- Diabetes Mellitus Type 2
- Non-alcoholic Steatohepatitis (NASH)
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Cardiomyopathy
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Obesity, Morbid
- Type 2 DM
- Type 2 DM /Diabetic Nephropathy
- Albuminuria
- Idiopathic Intracranial Hypertension
- Intracranial Pressure
- Pseudotumor Cerebri Syndrome
- Papilledema
- Major Depressive Disorder
- Mild Autonomous Cortisol Secretion (MACS)
- Autonomous Cortisol Secretion (ACS)
- Subclinical Cushing's
- Mild Autonomous Cortisol Excess
- Skeletal Muscle
- Brain Connectivity
- Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
- Aging
- Chronic Kidney Disease
- Dietary Change
- Food Acceptance
- Type 2 Diabetes Mellitus
- Nicotine Dependence, Cigarettes
- Obesity &Amp; Overweight
- Dental Care for Children
- Cardiovascular Diseases
- Acute Coronary Syndrome
- Coronary Artery Disease
- Longevity
- Mood
- Inflammation
- Immune Health
- Pain Management
- Alertness
- Osteoarthritis (OA) of the Knee
- Healthy Volunteers Diabetes Mellitus, Type 2
- Healthy Volunteers Overweight
- Healthy Volunteers Obesity
- Cognitive Decline in Older Adults
- Cigarette Smoking
- Marginal Ulcer (Peptic) or Erosion
- Leakage, Anastomotic
- Acute Ischemic Stroke
- Adiposity
- Fatty Liver
- Childhood Obesity
- Treatment Adherence
- Metabolism and Nutrition Disorder
- Cognitive Change
- Diabetic Peripheral Neuropathy
- Nicotine Addiction
- Tobacco Dependence
- Prediabetes / Type 2 Diabetes
- Short Bowel Syndrome (SBS)
- Intestinal Failure
- Obesity in Diabetes
- Obesity/Therapy
- Type 1 Diabetes Mellitus (T1DM)
- Insulin Sensitivity/Resistance
- Lipidomics
- Metabolomics
- Glycemic Control for Diabetes Mellitus
- Menopause
- Menopause Hot Flashes
- Menopause Related Conditions
- Cardiovascular
- Obesity; Drug
- Glucose Intolerance After a Recent History of Gestational Diabetes
- Overweight or Obesity
- Type2Diabetes
- ASCVD
- Alzheimer Dementia (AD)
- Intestinal Mucositis
- Chemotherapeutic Toxicity
- Steroid-Induced Diabetes
- Steroid Induced Hyperglycemia
- Severe Mental Illness
- Depression / Major Depressive Disorder
- Bipolar Disorder (BD)
- Schizophrenia
- PCOS
- Taste, Altered
- Tongue Tissue Transcriptome
- Gastric Emptying
- Central Neural Response
- Hepatic Impairment
- Adult Obesity
- Diabetic Patients
- Acute Myocardial Infarction
- Obesity and Obesity-related Medical Conditions
- Psychiatric Disorders
- Overweight and/or Obesity
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Liver Fibrosis
- Type 1 Diabetes Mellitus
- Type2diabetes
- Protein Supplementation
- Alzheimer Disease
- Mild Cognitive Impairment
- Semaglutide-Induced Gastric Motility
- Anesthesia
- Duchenne Muscular Dystrophy (DMD)
- Endometrial Hyperplasia
- Endometrial Cancer
- Endometrial Cancer Stage I
- Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I
- Atypical Endometrial Hyperplasia
- Endometrial Intraepithelial Neoplasia
- BMI>40
- Obesity Grade III
- Abdominal Wall Hernia
- Atrial Fibrillation
- Chronic Kidney Disease(CKD)
- HIV/AIDS
- Lipohypertrophy
- Micronutrient Deficiencies
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Non-alcoholic Steatohepatitis
- Liver Fat
- Tobacco Use
- Diabetes Mellitus, Type 1
- Hypertriglyceridemia Induced Acute Pancreatitis
- Recurrent Acute Pancreatitis
- Pancreatitis Relapsing
- Hypertriglyceridemia
- Diabetic Kidney Disease
- Alzheimers Disease
- Primary Open Angle Glaucoma (POAG)
- Open-Angle Glaucoma
- Glaucoma
- Bariatric Surgery Patients
- Psoriasis Arthritis
- Kidney Failure
- Hepatobiliary Disorders
- Klinefelter Syndrome
- Pre-Diabetes
- Weight, Body
- Type2 Diabetes
- High Blood Cholesterol Levels
- Kidney Disease, Chronic
- Dialysis
- End Stage Kidney Disease (ESRD)
- Chronic Inflammation
- Intestinal Permeability
- Digestive Disorders
- Cocaine Use Disorder
- Methamphetamine-dependence
- Bipolar I Disorder
- Bipolar II Disorder
- Schizo Affective Disorder
- Class I/II Obesity
- Glucose Metabolism Disorders (Including Diabetes Mellitus)
- Diabetes Type 1
- Endothelial Dysfunction
- Biomarkers
- Endothelial Progenitor Cells
- SGLT 2 Inhibitors
- Incretins
- Glucose Excursions
- FMD
- FPF
- Arterial Stiffness
- Heart Valve Prosthesis
- Obesity-related Male Infertility
- Cardiovascular Disease
- Omega-3 Fatty Acids
- PreDiabetes
- Schizophrenia Spectrum Disorders
- HFpEF - Heart Failure With Preserved Ejection Fraction
- Diabetic Cardiomyopathies
- Endometrioid Endometrial Adenocarcinoma
- Metformin
- Obesity, Abdominal
- Abdominal Fat
- Metabolism Disorder, Glucose
- Metabolism Disorder, Lipid
- Osteopenia
- Asthma
- Adolescent Obesity
- NAFLD
- Metabolic Disturbance
- Clozapine
- GLP-1
- Olanzapine
- Obesity Prevention
- Obesity Recidivism
- Ablation Techniques
- Atrial Fibrillation (AF)
- Adults With Overweight/Obesity and Type 2 Diabetes
- Muscle Wasting
- Healthy Volunteers (Diabetes Mellitus, Type 2)
- Body Composition
- HIV
- Brown Adipose Tissue
- Overweight (BMI > 25)
- Atherosclerosis
- Stroke (CVA) or Transient Ischemic Attack
- GLP-1 Concentration
- MAFLD
- Alzheimer Disease (AD)
- Weight Maintenance
- Cerebral Small Vessel Disease
- Prostate Carcinoma
- Recurrent Prostate Carcinoma
- Obese
- Obese Patients
- Iron Absorption
- Obesity/Overweight in Adult
- Obesity in Children
- Bone Strength
- Lifestyle Modification
- Bone Density
- Caloric Restriction
- Kidney Transplant Recipients
- Facial Skin Laxity
- Healthy Volunteer Study
- HPA
- Cortisol Deficiency
- Adrenal Insufficiency
- Nausea and Vomiting
- Cystic Fibrosis
- Cystic Fibrosis-related Diabetes
- Alcohol Use Disorder (AUD)
- Liver Transplant; Complications
- NASH - Nonalcoholic Steatohepatitis
- Foot Ulcer Due to Type 2 Diabetes Mellitus
- Cerebrovascular Disease
- Non-diabetic Obesity
- Impaired Glucose Tolerance
- Hyperglycemia
- Renal Transplant Complication Primary Non-Function
- Heart Failure With Reduced Ejection Fraction
- Chronic Heart Failure
- Cannabis Use Disorder
- Cannabis Use Disorders
- Cannabis Abuse
- Cannabis Dependence
- Cannabis Addiction
- PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
- Fibrosis, Liver
- Type 2 Diabetes Mellitus in Obese
- Pharmacokinetics
- Safety Issues
- Bioequivalence
- Spinal Cord Injuries
- Insulin Resistance
- Pre Diabetes
- Polycystic Ovary Syndrome
- Trichotillomania (Hair-Pulling Disorder)
- Trichotillomania
- Hair Pulling Disorder
- Hair Pulling
- Hair-Pulling Disorder
- Covid19
- Myocardial Injury
- Obesity Type 2 Diabetes Mellitus
- Atheroscleroses, Coronary
- Nonalcoholic Fatty Liver Disease
- STEMI - ST Elevation Myocardial Infarction
- Epicardial Fat
- Genetic Predisposition
- Metabolic Diseases
- Triglycerides
- Weight Gain Trajectory
- Cholesterol, Elevated
- Body-Weight Trajectory
- Weight Loss Trajectory
- Bariatric Surgery
- Anti-obesity Agents
- Geroscience
- PCOS (Polycystic Ovary Syndrome)
- Homeostasis
- Probiotic Intervention
- Insulin Sensitivity
- Heart Failure Preserved Ejection Fraction
- Epicardial Adipose Tissue
- Morbid Obesity
- Hypertension
- Obstructive Sleep Apnea of Adult
- Alcohol
- Smoking Cigarette
- Cardiovascular Disease Prevention
- Depression
- Obesity and Metabolic Syndrome
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Chronic Weight Management
- Prediabetic State
- Osteoporosis
- Osteoporosis Fracture
- T2DM
- Rectal Cancer Patients
- Locally Advanced Rectal Cancer (LARC)
- Total Neoadjuvant Therapy
- Postpartum Disorder
- Diabete Type 2
- Weight Change, Body
- Functional Hypogonadism
- Early Alzheimer´s Disease
- HIV-1-infection
- Methamphetamine Use Disorder
- Double Diabetes
- Aortic Stenosis
- Obesity Control
- Intracerebral Hemorrhage
- Acute Myocardial Infarction With ST Elevation
- Addiction
- Metabolism and Nutrition Disorders
- Type II Diabetes
- Large Vessel Occlusion
- Neuroprotective Drugs
- Endovascular Treatment
- Parkinson Disease
- Non-Alcoholic Steatohepatitis
- Obesity, Adolescent
- Ischemic Stroke
- Diabetes type1
- Diabete Mellitus
- Tobacco Use Disorder
- Interstitial Lung Disease
- Chronic Obstructive Pulmonary Disease
- Sarcoidosis, Pulmonary
- Pulmonary Hypertension
- CKD
- Early Alzheimer's Disease
- Normal Weight
- Pancreatic Cancer
- Colorectal Cancer
- Hepatocellular Carcinoma
- Disordered Eating Behaviors
- Hepatic Impaired
- Fatty Liver, Nonalcoholic
- Prediabetes
- Chronic Coronary Syndrome
- T2DM (Type 2 Diabetes Mellitus)
- End Stage Renal Disease on Dialysis

## Every trial on record

| Trial ID | Title | Condition | Phase | Status | Enrolled |
|---|---|---|---|---|---|
| [NCT02827708](https://clinicaltrials.gov/study/NCT02827708) | Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 324 |
| [NCT06946628](https://clinicaltrials.gov/study/NCT06946628) | New Triple Therapy in Newly Diagnosed Type 2 Diabetes | Diabetes Mellitus | Phase 3 | NOT_YET_RECRUITING | 296 |
| [NCT07554417](https://clinicaltrials.gov/study/NCT07554417) | Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 | GLP - 1, Obesity & Overweight | Phase 4 | NOT_YET_RECRUITING | 20 |
| [NCT03987074](https://clinicaltrials.gov/study/NCT03987074) | Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 109 |
| [NCT06118008](https://clinicaltrials.gov/study/NCT06118008) | A Study of HS-20094 in T2DM Participants | Type 2 Diabetes | Phase 2 | COMPLETED | 54 |
| [NCT05173714](https://clinicaltrials.gov/study/NCT05173714) | Sit Less, Interact and Move More (SLIMM) 2 Study | Chronic Kidney Diseases, Obesity | Phase 2 | RECRUITING | 156 |
| [NCT05895643](https://clinicaltrials.gov/study/NCT05895643) | Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? | Alcohol Abuse, Alcohol Addiction | Phase 2 | COMPLETED | 108 |
| [NCT04560998](https://clinicaltrials.gov/study/NCT04560998) | A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Diabetes Mellitus, Type 2, Peripheral Arterial Disease | Phase 3 | COMPLETED | 792 |
| [NCT06934655](https://clinicaltrials.gov/study/NCT06934655) | Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth | Pediatric Obesity, Metabolic and Bariatric Surgery | Phase 3 | NOT_YET_RECRUITING | 150 |
| [NCT04216589](https://clinicaltrials.gov/study/NCT04216589) | Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | HIV Infections, Non-Alcoholic Fatty Liver Disease | Phase 2 | COMPLETED | 51 |
| [NCT07073053](https://clinicaltrials.gov/study/NCT07073053) | The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms | Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes | Phase 4 | NOT_YET_RECRUITING | 60 |
| [NCT06461377](https://clinicaltrials.gov/study/NCT06461377) | The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis) | Phase 4 | RECRUITING | 50 |
| [NCT05813249](https://clinicaltrials.gov/study/NCT05813249) | Semaglutide in Nonalcoholic Fatty Liver Disease | Non-alcoholic Fatty Liver Disease | Phase 4 | COMPLETED | 180 |
| [NCT06409130](https://clinicaltrials.gov/study/NCT06409130) | Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease | Alcohol-related Liver Disease | Phase 2 | COMPLETED | 270 |
| [NCT07446998](https://clinicaltrials.gov/study/NCT07446998) | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | Obesity & Overweight, Mobility Disability | Phase 2 | RECRUITING | 200 |
| [NCT05073835](https://clinicaltrials.gov/study/NCT05073835) | Semaglutide 2.4 mg in Patients With Poor Weight-loss | Obesity, Diabetes | Phase 3 | ACTIVE_NOT_RECRUITING | 70 |
| [NCT07293325](https://clinicaltrials.gov/study/NCT07293325) | Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | Adults With Simple Obesity | Not phased | RECRUITING | 66 |
| [NCT07570810](https://clinicaltrials.gov/study/NCT07570810) | Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM | Type 2 Diabetes, Obesity | Not phased | NOT_YET_RECRUITING | 30 |
| [NCT07271251](https://clinicaltrials.gov/study/NCT07271251) | A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | ACTIVE_NOT_RECRUITING | 264 |
| [NCT06045221](https://clinicaltrials.gov/study/NCT06045221) | A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Type 2 Diabetes | Phase 3 | COMPLETED | 1698 |
| [NCT05646706](https://clinicaltrials.gov/study/NCT05646706) | A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) | Obesity | Phase 3 | COMPLETED | 1407 |
| [NCT06764056](https://clinicaltrials.gov/study/NCT06764056) | Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) | Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH) | Not phased | NOT_YET_RECRUITING | 120 |
| [NCT07325435](https://clinicaltrials.gov/study/NCT07325435) | Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists | Type 2 Diabetes (T2DM) | Phase 4 | ACTIVE_NOT_RECRUITING | 60 |
| [NCT06913023](https://clinicaltrials.gov/study/NCT06913023) | Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus | Kidney Transplant Recipient | Phase 3 | NOT_YET_RECRUITING | 74 |
| [NCT06778967](https://clinicaltrials.gov/study/NCT06778967) | A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM) | Phase 3 | ACTIVE_NOT_RECRUITING | 1100 |
| [NCT07711548](https://clinicaltrials.gov/study/NCT07711548) | Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity? | Obesity & Overweight, Weight Loss Maintenance | Not phased | NOT_YET_RECRUITING | 292 |
| [NCT03015220](https://clinicaltrials.gov/study/NCT03015220) | Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 458 |
| [NCT05132088](https://clinicaltrials.gov/study/NCT05132088) | Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Overweight and Obesity | Phase 3 | COMPLETED | 201 |
| [NCT06292065](https://clinicaltrials.gov/study/NCT06292065) | Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy | Gastroparesis | Not phased | COMPLETED | 88 |
| [NCT03191396](https://clinicaltrials.gov/study/NCT03191396) | Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 577 |
| [NCT07187856](https://clinicaltrials.gov/study/NCT07187856) | Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM) | Phase 2 | NOT_YET_RECRUITING | 80 |
| [NCT01885208](https://clinicaltrials.gov/study/NCT01885208) | Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 813 |
| [NCT04878406](https://clinicaltrials.gov/study/NCT04878406) | A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men | Healthy Volunteers Type 2 Diabetes | Phase 1 | COMPLETED | 24 |
| [NCT07325500](https://clinicaltrials.gov/study/NCT07325500) | Incretin Microdosing for Cardiometabolic Health in People With HIV | Weight Gain | Phase 2 | RECRUITING | 30 |
| [NCT03819153](https://clinicaltrials.gov/study/NCT03819153) | A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 3533 |
| [NCT01930188](https://clinicaltrials.gov/study/NCT01930188) | Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1231 |
| [NCT04596631](https://clinicaltrials.gov/study/NCT04596631) | A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 132 |
| [NCT04109508](https://clinicaltrials.gov/study/NCT04109508) | A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets | Healthy Volunteers, Type 2 Diabetes | Phase 1 | COMPLETED | 278 |
| [NCT05514535](https://clinicaltrials.gov/study/NCT05514535) | A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | Diabetes Mellitus, Type 2, Obesity | Phase 3 | COMPLETED | 573 |
| [NCT05521256](https://clinicaltrials.gov/study/NCT05521256) | A Research Study of a New Medicine NNC0113-6856 in Healthy Males | Healthy Volunteers, Type 2 Diabetes | Phase 1 | COMPLETED | 70 |
| [NCT06827002](https://clinicaltrials.gov/study/NCT06827002) | Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults | Obesity and Overweight, Appetite Regulation | Phase 2 | ACTIVE_NOT_RECRUITING | 248 |
| [NCT00833716](https://clinicaltrials.gov/study/NCT00833716) | Effect of Renal Impairment on the Pharmacokinetics of NN9535 | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 62 |
| [NCT05196958](https://clinicaltrials.gov/study/NCT05196958) | Interest of GLP1 Analogues in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease | Inflammatory Bowel Diseases, Diabetes Mellitus, Type 2 | Not phased | UNKNOWN | 20 |
| [NCT06548490](https://clinicaltrials.gov/study/NCT06548490) | GLP-1R Agonist Treatment for Opioid Use Disorder | Opioid Use Disorder, Opioid Abuse and Addiction | Phase 2 | RECRUITING | 200 |
| [NCT03466567](https://clinicaltrials.gov/study/NCT03466567) | A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 21 |
| [NCT06908694](https://clinicaltrials.gov/study/NCT06908694) | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy | Prostate Cancer | Phase 4 | RECRUITING | 20 |
| [NCT05441267](https://clinicaltrials.gov/study/NCT05441267) | A Study of Cardiovascular Events iN Diabetes Plus | Diabetes Mellitus, Type 2 | Phase 4 | ACTIVE_NOT_RECRUITING | 21296 |
| [NCT05040971](https://clinicaltrials.gov/study/NCT05040971) | Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes | Obesity | Phase 3 | COMPLETED | 207 |
| [NCT06387199](https://clinicaltrials.gov/study/NCT06387199) | Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide | Type 1 Diabetes, Diabetes Mellitus | Phase 3 | RECRUITING | 26 |
| [NCT01324505](https://clinicaltrials.gov/study/NCT01324505) | Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 43 |
| [NCT07242534](https://clinicaltrials.gov/study/NCT07242534) | Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. | Infertility, Obesity | Phase 4 | RECRUITING | 62 |
| [NCT07357766](https://clinicaltrials.gov/study/NCT07357766) | A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight | Overweight, Obesity | Phase 3 | WITHDRAWN | 0 |
| [NCT07430332](https://clinicaltrials.gov/study/NCT07430332) | GLP-1 RA for Stage 1 Type 1 Diabetes | Stage 1 Diabetes Mellitus, Type 1 | Phase 2 | NOT_YET_RECRUITING | 15 |
| [NCT02014259](https://clinicaltrials.gov/study/NCT02014259) | Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 71 |
| [NCT05784402](https://clinicaltrials.gov/study/NCT05784402) | A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants | Healthy Participants | Phase 1 | COMPLETED | 264 |
| [NCT05533632](https://clinicaltrials.gov/study/NCT05533632) | Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 104 |
| [NCT06977438](https://clinicaltrials.gov/study/NCT06977438) | GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward | Obesity, Childhood | Phase 4 | NOT_YET_RECRUITING | 1020 |
| [NCT07628985](https://clinicaltrials.gov/study/NCT07628985) | BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Phase 3 | NOT_YET_RECRUITING | 374 |
| [NCT06974825](https://clinicaltrials.gov/study/NCT06974825) | A Study of BGM0504 in Chinese Patients With Type 2 Diabetes | Type 2 Diabetes | Phase 2 | COMPLETED | 67 |
| [NCT06896981](https://clinicaltrials.gov/study/NCT06896981) | Semaglutide in Women With Polycystic Ovary Syndrome and Obesity | Polycystic Ovary Syndrome (PCOS) Women, Obesity | Phase 3 | RECRUITING | 30 |
| [NCT06634927](https://clinicaltrials.gov/study/NCT06634927) | Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. | Type 2 Diabetes | Phase 1 | COMPLETED | 68 |
| [NCT04061200](https://clinicaltrials.gov/study/NCT04061200) | Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria | Type 2 Diabetes With Renal Manifestations | Phase 4 | UNKNOWN | 80 |
| [NCT05812183](https://clinicaltrials.gov/study/NCT05812183) | Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity | Dyspnea, Quality of Life | Phase 4 | WITHDRAWN | 0 |
| [NCT04880005](https://clinicaltrials.gov/study/NCT04880005) | Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid | Diabetes type2 | Not phased | RECRUITING | 400 |
| [NCT06400615](https://clinicaltrials.gov/study/NCT06400615) | Study That Tests AD109 in Patients Taking GLP-1 Drugs | OSA | Phase 2 | COMPLETED | 40 |
| [NCT05822830](https://clinicaltrials.gov/study/NCT05822830) | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Obesity, Overweight | Phase 3 | COMPLETED | 751 |
| [NCT06801015](https://clinicaltrials.gov/study/NCT06801015) | Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions | Obesity | Phase 4 | ACTIVE_NOT_RECRUITING | 30 |
| [NCT05920889](https://clinicaltrials.gov/study/NCT05920889) | Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies | Stroke, Stroke, Acute | Phase 2 | COMPLETED | 140 |
| [NCT05813925](https://clinicaltrials.gov/study/NCT05813925) | A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight | Obesity or Overweight | Phase 3 | COMPLETED | 331 |
| [NCT07058155](https://clinicaltrials.gov/study/NCT07058155) | Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease | Liver Cirrhoses, Portal Hypertension Related to Cirrhosis | Phase 4 | RECRUITING | 70 |
| [NCT07184086](https://clinicaltrials.gov/study/NCT07184086) | A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | Obesity | Phase 1 | RECRUITING | 80 |
| [NCT06149260](https://clinicaltrials.gov/study/NCT06149260) | Subcutaneous Semaglutide in Systemic Scleroderma | Scleroderma, Systemic, Fibrosis | Phase 1 | UNKNOWN | 10 |
| [NCT04916470](https://clinicaltrials.gov/study/NCT04916470) | Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 617 |
| [NCT04990024](https://clinicaltrials.gov/study/NCT04990024) | The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide | Obesity, Weight Loss | Not phased | RECRUITING | 60 |
| [NCT07513168](https://clinicaltrials.gov/study/NCT07513168) | Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults | Obesity, Weight Reduction | Phase 4 | RECRUITING | 60 |
| [NCT06541509](https://clinicaltrials.gov/study/NCT06541509) | Mechanisms of Semaglutide Therapy in Heart Failure Patients | Heart Failure, Obesity | Phase 2 | RECRUITING | 10 |
| [NCT06475586](https://clinicaltrials.gov/study/NCT06475586) | Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus | Psoriasis Vulgaris, Diabetes Type 2 | Phase 4 | COMPLETED | 30 |
| [NCT06298799](https://clinicaltrials.gov/study/NCT06298799) | GENETIC VARIABILITY TO GLP1 TREATMENT | Type 2 Diabetes, Obesity | Not phased | UNKNOWN | 400 |
| [NCT06604624](https://clinicaltrials.gov/study/NCT06604624) | Semaglutide in Treatment of Obesity | Weight Management | Phase 3 | COMPLETED | 462 |
| [NCT07401992](https://clinicaltrials.gov/study/NCT07401992) | Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | Psoriasis (PsO), Obesity & Overweight | Phase 4 | RECRUITING | 62 |
| [NCT07294950](https://clinicaltrials.gov/study/NCT07294950) | Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination | Obesity (Disorder), Weight Change | Phase 3 | RECRUITING | 98 |
| [NCT05751226](https://clinicaltrials.gov/study/NCT05751226) | A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 | Healthy, Obesity | Phase 1 | COMPLETED | 88 |
| [NCT07317115](https://clinicaltrials.gov/study/NCT07317115) | Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes | Obesity (Disorder), Obesity & Overweight | Not phased | RECRUITING | 20 |
| [NCT06851962](https://clinicaltrials.gov/study/NCT06851962) | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. | Diabetes Mellitus Type 2 | Phase 4 | ACTIVE_NOT_RECRUITING | 504 |
| [NCT04639414](https://clinicaltrials.gov/study/NCT04639414) | Combined Active Treatment in Type 2 Diabetes With NASH | Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH) | Phase 4 | COMPLETED | 192 |
| [NCT05371496](https://clinicaltrials.gov/study/NCT05371496) | Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction | Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 4 | ENROLLING_BY_INVITATION | 81 |
| [NCT06739044](https://clinicaltrials.gov/study/NCT06739044) | Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | COMPLETED | 494 |
| [NCT06287307](https://clinicaltrials.gov/study/NCT06287307) | Semaglutide 2.4mg for Low Responders After Bariatric Surgery | Obesity, Obesity, Morbid | Phase 4 | NOT_YET_RECRUITING | 152 |
| [NCT02305381](https://clinicaltrials.gov/study/NCT02305381) | Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 397 |
| [NCT06954090](https://clinicaltrials.gov/study/NCT06954090) | Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study | Type 2 DM, Type 2 DM /Diabetic Nephropathy | Phase 4 | ENROLLING_BY_INVITATION | 50 |
| [NCT03693430](https://clinicaltrials.gov/study/NCT03693430) | Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Overweight, Obesity | Phase 3 | COMPLETED | 304 |
| [NCT05444153](https://clinicaltrials.gov/study/NCT05444153) | Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity | Diabetes Mellitus, Type 2 | Phase 3 | WITHDRAWN | 0 |
| [NCT05579249](https://clinicaltrials.gov/study/NCT05579249) | A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America | Obesity | Phase 4 | COMPLETED | 500 |
| [NCT07163624](https://clinicaltrials.gov/study/NCT07163624) | UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study | Type 2 Diabetes Mellitus (T2DM) | Phase 2 | COMPLETED | 211 |
| [NCT06027567](https://clinicaltrials.gov/study/NCT06027567) | The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure | Idiopathic Intracranial Hypertension, Intracranial Pressure | Phase 4 | COMPLETED | 38 |
| [NCT07136714](https://clinicaltrials.gov/study/NCT07136714) | Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity | Major Depressive Disorder | Phase 4 | RECRUITING | 116 |
| [NCT02016911](https://clinicaltrials.gov/study/NCT02016911) | Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 56 |
| [NCT06616961](https://clinicaltrials.gov/study/NCT06616961) | Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus | Obesity, Type 2 Diabetes Mellitus (T2DM) | Phase 3 | NOT_YET_RECRUITING | 480 |
| [NCT07361874](https://clinicaltrials.gov/study/NCT07361874) | IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion | Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Not phased | RECRUITING | 75 |
| [NCT01572753](https://clinicaltrials.gov/study/NCT01572753) | Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 161 |
| [NCT07280403](https://clinicaltrials.gov/study/NCT07280403) | Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss | Weight Loss | Not phased | COMPLETED | 60 |
| [NCT07091500](https://clinicaltrials.gov/study/NCT07091500) | Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity | Obesity, Skeletal Muscle | Not phased | RECRUITING | 40 |
| [NCT06534411](https://clinicaltrials.gov/study/NCT06534411) | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1023 |
| [NCT07713992](https://clinicaltrials.gov/study/NCT07713992) | Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide | Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus | Not phased | NOT_YET_RECRUITING | 72 |
| [NCT03914326](https://clinicaltrials.gov/study/NCT03914326) | A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 9651 |
| [NCT06762314](https://clinicaltrials.gov/study/NCT06762314) | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | Diabetes | Phase 2 | RECRUITING | 105 |
| [NCT07668414](https://clinicaltrials.gov/study/NCT07668414) | A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide | Overweight, Obesity | Phase 3 | NOT_YET_RECRUITING | 650 |
| [NCT05302596](https://clinicaltrials.gov/study/NCT05302596) | Semaglutide Use in Elderly Obese Patients | Obesity, Aging | Phase 2 | COMPLETED | 16 |
| [NCT07547878](https://clinicaltrials.gov/study/NCT07547878) | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | NOT_YET_RECRUITING | 64 |
| [NCT07244458](https://clinicaltrials.gov/study/NCT07244458) | Dietary Peanuts and Nutrition-Related Outcomes | Dietary Change, Obesity & Overweight | Not phased | RECRUITING | 64 |
| [NCT02648204](https://clinicaltrials.gov/study/NCT02648204) | Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1201 |
| [NCT07112872](https://clinicaltrials.gov/study/NCT07112872) | A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 2 | ACTIVE_NOT_RECRUITING | 240 |
| [NCT06396416](https://clinicaltrials.gov/study/NCT06396416) | Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2 | Obesity, Chronic Kidney Disease | Phase 4 | RECRUITING | 60 |
| [NCT06924697](https://clinicaltrials.gov/study/NCT06924697) | Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients | Diabetes Mellitus, Type 2, Nicotine Dependence, Cigarettes | Not phased | ENROLLING_BY_INVITATION | 46 |
| [NCT03707990](https://clinicaltrials.gov/study/NCT03707990) | A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese | Obesity and Overweight | Phase 1 | COMPLETED | 88 |
| [NCT07171723](https://clinicaltrials.gov/study/NCT07171723) | Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment | Obesity &Amp; Overweight | Phase 2 | RECRUITING | 24 |
| [NCT06804603](https://clinicaltrials.gov/study/NCT06804603) | A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use | Obesity | Phase 2 | COMPLETED | 124 |
| [NCT07478653](https://clinicaltrials.gov/study/NCT07478653) | MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease | Obesity, Dental Care for Children | Not phased | NOT_YET_RECRUITING | 50 |
| [NCT07483801](https://clinicaltrials.gov/study/NCT07483801) | DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | Cardiovascular Diseases | Phase 4 | NOT_YET_RECRUITING | 112 |
| [NCT06584916](https://clinicaltrials.gov/study/NCT06584916) | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | Obesity, Overweight | Phase 3 | COMPLETED | 376 |
| [NCT07253285](https://clinicaltrials.gov/study/NCT07253285) | A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | Overweight, Obesity | Phase 3 | RECRUITING | 460 |
| [NCT05322200](https://clinicaltrials.gov/study/NCT05322200) | The POST-ACS Study | Diabetes Mellitus, Acute Coronary Syndrome | Phase 4 | UNKNOWN | 140 |
| [NCT05996848](https://clinicaltrials.gov/study/NCT05996848) | A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight | Obesity or Overweight | Phase 3 | COMPLETED | 300 |
| [NCT07092605](https://clinicaltrials.gov/study/NCT07092605) | Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures | Longevity, Quality of Life | Phase 1 | ENROLLING_BY_INVITATION | 150 |
| [NCT06807970](https://clinicaltrials.gov/study/NCT06807970) | Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist | Osteoarthritis (OA) of the Knee | Phase 1 | NOT_YET_RECRUITING | 54 |
| [NCT04007107](https://clinicaltrials.gov/study/NCT04007107) | A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity | Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight | Phase 2 | COMPLETED | 103 |
| [NCT07218354](https://clinicaltrials.gov/study/NCT07218354) | Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder | Alcohol Use Disorder | Phase 3 | NOT_YET_RECRUITING | 622 |
| [NCT07485062](https://clinicaltrials.gov/study/NCT07485062) | Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes | Type 2 Diabetes, Cognitive Decline in Older Adults | Phase 4 | NOT_YET_RECRUITING | 164 |
| [NCT06173778](https://clinicaltrials.gov/study/NCT06173778) | Semaglutide for Post-Smoking Cessation Weight Management | Obesity, Overweight | Phase 2 | RECRUITING | 197 |
| [NCT07495020](https://clinicaltrials.gov/study/NCT07495020) | The Transit Bipartition With the Use of a Metallic Anastomosis Clip and Circular Fundocorporeal Gastroplication | Type 2 Diabetes Mellitus (T2DM), Obesity & Overweight | Not phased | RECRUITING | 90 |
| [NCT05630586](https://clinicaltrials.gov/study/NCT05630586) | Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke | Acute Ischemic Stroke | Phase 2 | RECRUITING | 380 |
| [NCT06546384](https://clinicaltrials.gov/study/NCT06546384) | GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | Adiposity, Fatty Liver | Not phased | NOT_YET_RECRUITING | 64 |
| [NCT06836284](https://clinicaltrials.gov/study/NCT06836284) | The Evira Study: Additional Support During Obesity Treatment | Childhood Obesity, Treatment Adherence | Not phased | RECRUITING | 40 |
| [NCT05390307](https://clinicaltrials.gov/study/NCT05390307) | Obesity Treatment to Improve Diabetes | Type 1 Diabetes | Not phased | COMPLETED | 60 |
| [NCT02453711](https://clinicaltrials.gov/study/NCT02453711) | Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Metabolism and Nutrition Disorder, Obesity | Phase 2 | COMPLETED | 957 |
| [NCT07284979](https://clinicaltrials.gov/study/NCT07284979) | Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Obesity | Phase 3 | RECRUITING | 1200 |
| [NCT06363487](https://clinicaltrials.gov/study/NCT06363487) | Semaglutide and Cognition in Healthy Volunteers | Cognitive Change | Not phased | COMPLETED | 70 |
| [NCT04126603](https://clinicaltrials.gov/study/NCT04126603) | Impact of Semaglutide on CD34+ EPC and Fat Derived MSC | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 10 |
| [NCT07011667](https://clinicaltrials.gov/study/NCT07011667) | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 609 |
| [NCT07564414](https://clinicaltrials.gov/study/NCT07564414) | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Obesity, Type 2 Diabetes | Phase 3 | RECRUITING | 2500 |
| [NCT06797869](https://clinicaltrials.gov/study/NCT06797869) | A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy | Phase 2 | ACTIVE_NOT_RECRUITING | 142 |
| [NCT07059377](https://clinicaltrials.gov/study/NCT07059377) | Semaglutide for Smoking Cessation in Patients With Diabetes | Diabetes Mellitus, Type 2, Nicotine Addiction | Phase 3 | RECRUITING | 100 |
| [NCT07195994](https://clinicaltrials.gov/study/NCT07195994) | A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes | Prediabetes / Type 2 Diabetes | Not phased | RECRUITING | 90 |
| [NCT04817644](https://clinicaltrials.gov/study/NCT04817644) | A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 14 |
| [NCT07297238](https://clinicaltrials.gov/study/NCT07297238) | Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration. | Short Bowel Syndrome (SBS), Intestinal Failure | Not phased | COMPLETED | 20 |
| [NCT06909006](https://clinicaltrials.gov/study/NCT06909006) | Semaglutide Treatment in Type 1 Diabetes | Obesity in Diabetes, Obesity/Therapy | Phase 3 | NOT_YET_RECRUITING | 122 |
| [NCT07668388](https://clinicaltrials.gov/study/NCT07668388) | A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | RECRUITING | 300 |
| [NCT06975111](https://clinicaltrials.gov/study/NCT06975111) | Focusing on the Menopausal Transition to Improve Mid-Life Women's Health | Menopause, Menopause Hot Flashes | Phase 3 | RECRUITING | 200 |
| [NCT06131372](https://clinicaltrials.gov/study/NCT06131372) | A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | COMPLETED | 626 |
| [NCT06431308](https://clinicaltrials.gov/study/NCT06431308) | Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events | Obesity; Drug | Not phased | RECRUITING | 120 |
| [NCT05569772](https://clinicaltrials.gov/study/NCT05569772) | Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes | Glucose Intolerance After a Recent History of Gestational Diabetes | Phase 3 | RECRUITING | 252 |
| [NCT03548935](https://clinicaltrials.gov/study/NCT03548935) | STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Metabolism and Nutrition Disorder, Overweight or Obesity | Phase 3 | COMPLETED | 1961 |
| [NCT05390892](https://clinicaltrials.gov/study/NCT05390892) | PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Type2Diabetes, ASCVD | Phase 4 | RECRUITING | 6000 |
| [NCT03811574](https://clinicaltrials.gov/study/NCT03811574) | STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity | Overweight, Obesity | Phase 3 | COMPLETED | 401 |
| [NCT07651319](https://clinicaltrials.gov/study/NCT07651319) | Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease | Alzheimer Dementia (AD) | Phase 2 | RECRUITING | 30 |
| [NCT06344247](https://clinicaltrials.gov/study/NCT06344247) | Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease | Obesity, Chronic Kidney Diseases | Not phased | UNKNOWN | 48 |
| [NCT06449625](https://clinicaltrials.gov/study/NCT06449625) | Semaglutide in Auto-HSCT | Intestinal Mucositis, Inflammation | Phase 2 | NOT_YET_RECRUITING | 40 |
| [NCT02161588](https://clinicaltrials.gov/study/NCT02161588) | A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 48 |
| [NCT06318442](https://clinicaltrials.gov/study/NCT06318442) | The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes | Steroid-Induced Diabetes, Steroid Induced Hyperglycemia | Not phased | RECRUITING | 60 |
| [NCT07073417](https://clinicaltrials.gov/study/NCT07073417) | A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) | Obesity, Weight Management | Phase 2 | ACTIVE_NOT_RECRUITING | 163 |
| [NCT07586150](https://clinicaltrials.gov/study/NCT07586150) | Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN) | Severe Mental Illness, Depression / Major Depressive Disorder | Not phased | NOT_YET_RECRUITING | 140 |
| [NCT06716216](https://clinicaltrials.gov/study/NCT06716216) | A Study of BGM0504 in Participants with Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Phase 3 | RECRUITING | 537 |
| [NCT06269107](https://clinicaltrials.gov/study/NCT06269107) | A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) | Type 2 Diabetes | Phase 3 | COMPLETED | 485 |
| [NCT04263415](https://clinicaltrials.gov/study/NCT04263415) | The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity | PCOS, Semaglutide | Phase 4 | COMPLETED | 30 |
| [NCT06426446](https://clinicaltrials.gov/study/NCT06426446) | Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data | Obesity | Not phased | UNKNOWN | 80 |
| [NCT04109547](https://clinicaltrials.gov/study/NCT04109547) | A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 521 |
| [NCT04259801](https://clinicaltrials.gov/study/NCT04259801) | First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes | Healthy Volunteers, Overweight | Phase 1 | COMPLETED | 152 |
| [NCT06468748](https://clinicaltrials.gov/study/NCT06468748) | The Effects of Semaglutide on Body Composition and Performance in Military Personnel | Obesity | Phase 4 | WITHDRAWN | 0 |
| [NCT05564104](https://clinicaltrials.gov/study/NCT05564104) | A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body | Hepatic Impairment, Healthy Volunteers | Phase 1 | COMPLETED | 32 |
| [NCT07505303](https://clinicaltrials.gov/study/NCT07505303) | MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial | Adult Obesity, Weight Management | Phase 2 | ACTIVE_NOT_RECRUITING | 151 |
| [NCT06083675](https://clinicaltrials.gov/study/NCT06083675) | Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | WITHDRAWN | 0 |
| [NCT06557811](https://clinicaltrials.gov/study/NCT06557811) | Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction | Diabetic Patients, Acute Myocardial Infarction | Phase 4 | NOT_YET_RECRUITING | 88 |
| [NCT07220629](https://clinicaltrials.gov/study/NCT07220629) | Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) | Obesity | Phase 2 | ACTIVE_NOT_RECRUITING | 82 |
| [NCT06131437](https://clinicaltrials.gov/study/NCT06131437) | A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | Obesity | Phase 3 | COMPLETED | 809 |
| [NCT06754163](https://clinicaltrials.gov/study/NCT06754163) | Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients | Obesity and Obesity-related Medical Conditions, Psychiatric Disorders | Phase 4 | ACTIVE_NOT_RECRUITING | 20 |
| [NCT07673900](https://clinicaltrials.gov/study/NCT07673900) | Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants | Overweight and/or Obesity | Phase 1 | RECRUITING | 62 |
| [NCT06374875](https://clinicaltrials.gov/study/NCT06374875) | Fibrosis Lessens After Metabolic Surgery | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease | Phase 4 | RECRUITING | 120 |
| [NCT03899402](https://clinicaltrials.gov/study/NCT03899402) | Triple Therapy in T1DM | Type 1 Diabetes Mellitus | Phase 3 | ACTIVE_NOT_RECRUITING | 78 |
| [NCT07728812](https://clinicaltrials.gov/study/NCT07728812) | Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy | Obesity & Overweight | Not phased | NOT_YET_RECRUITING | 424 |
| [NCT02128932](https://clinicaltrials.gov/study/NCT02128932) | Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1089 |
| [NCT07428746](https://clinicaltrials.gov/study/NCT07428746) | Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | NOT_YET_RECRUITING | 20 |
| [NCT06449235](https://clinicaltrials.gov/study/NCT06449235) | Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Type2diabetes | Phase 4 | NOT_YET_RECRUITING | 938 |
| [NCT06989203](https://clinicaltrials.gov/study/NCT06989203) | Protein Supplementation Intervention on Body Weight | Obesity, Weight Loss | Not phased | RECRUITING | 140 |
| [NCT07065383](https://clinicaltrials.gov/study/NCT07065383) | Rebalancing the Fat Content of the Heart and Muscles | Diabetes Mellitus Type 2 | Not phased | RECRUITING | 60 |
| [NCT07064486](https://clinicaltrials.gov/study/NCT07064486) | A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | Type 2 Diabetes (T2DM) | Phase 3 | RECRUITING | 477 |
| [NCT07487103](https://clinicaltrials.gov/study/NCT07487103) | Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | NOT_YET_RECRUITING | 478 |
| [NCT01766245](https://clinicaltrials.gov/study/NCT01766245) | A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes | Diabetes, Healthy | Phase 1 | COMPLETED | 28 |
| [NCT02906930](https://clinicaltrials.gov/study/NCT02906930) | Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 703 |
| [NCT06072963](https://clinicaltrials.gov/study/NCT06072963) | COMMETS- Combination MCI Metabolic Syndrome | Alzheimer Disease, Mild Cognitive Impairment | Phase 2 | RECRUITING | 80 |
| [NCT07254715](https://clinicaltrials.gov/study/NCT07254715) | Effect of Itopride on Semaglutide Gastroparesis | Semaglutide-Induced Gastric Motility, Anesthesia | Phase 4 | RECRUITING | 60 |
| [NCT07642635](https://clinicaltrials.gov/study/NCT07642635) | Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy (DMD) | Phase 2 | NOT_YET_RECRUITING | 30 |
| [NCT05567796](https://clinicaltrials.gov/study/NCT05567796) | A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 3400 |
| [NCT05829460](https://clinicaltrials.gov/study/NCT05829460) | Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia | Endometrial Hyperplasia | Phase 2 | WITHDRAWN | 0 |
| [NCT03144271](https://clinicaltrials.gov/study/NCT03144271) | Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 58 |
| [NCT05071898](https://clinicaltrials.gov/study/NCT05071898) | Pharmacogenetics of Response to GLP1R Agonists | Obesity, Diabetes Type 2 | Phase 1 | RECRUITING | 600 |
| [NCT07462663](https://clinicaltrials.gov/study/NCT07462663) | SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer | Endometrial Cancer, Endometrial Cancer Stage I | Phase 4 | NOT_YET_RECRUITING | 80 |
| [NCT05925959](https://clinicaltrials.gov/study/NCT05925959) | Preoperative Weight Loss for Open Abdominal Wall Reconstruction | Abdominal Wall Hernia | Not phased | RECRUITING | 258 |
| [NCT05984238](https://clinicaltrials.gov/study/NCT05984238) | A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2) | Diabetes Mellitus, Type 2 | Not phased | COMPLETED | 33 |
| [NCT06885736](https://clinicaltrials.gov/study/NCT06885736) | LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy | Obesity | Not phased | RECRUITING | 232 |
| [NCT01923181](https://clinicaltrials.gov/study/NCT01923181) | Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 632 |
| [NCT03600480](https://clinicaltrials.gov/study/NCT03600480) | A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese | Obesity, Overweight | Phase 1 | COMPLETED | 96 |
| [NCT05209165](https://clinicaltrials.gov/study/NCT05209165) | Semaglutide to Reduce Atrial Fibrillation Burden | Atrial Fibrillation, Obesity | Phase 4 | SUSPENDED | 132 |
| [NCT07239570](https://clinicaltrials.gov/study/NCT07239570) | A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease | Chronic Kidney Disease(CKD) | Phase 4 | RECRUITING | 125 |
| [NCT04019197](https://clinicaltrials.gov/study/NCT04019197) | Effects of Semaglutide in HIV-Associated Lipohypertrophy | HIV/AIDS, Lipohypertrophy | Phase 2 | ACTIVE_NOT_RECRUITING | 108 |
| [NCT01619345](https://clinicaltrials.gov/study/NCT01619345) | Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 27 |
| [NCT06981936](https://clinicaltrials.gov/study/NCT06981936) | This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control | Micronutrient Deficiencies | Phase 4 | RECRUITING | 150 |
| [NCT06716307](https://clinicaltrials.gov/study/NCT06716307) | A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity | Obesity | Phase 1 | COMPLETED | 18 |
| [NCT07466017](https://clinicaltrials.gov/study/NCT07466017) | A Study of CS060380 Tablets in Patients With MASH and Obesity | Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity | Phase 2 | RECRUITING | 120 |
| [NCT03021187](https://clinicaltrials.gov/study/NCT03021187) | Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 731 |
| [NCT05751720](https://clinicaltrials.gov/study/NCT05751720) | Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue | Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis | Phase 2 | UNKNOWN | 30 |
| [NCT06161844](https://clinicaltrials.gov/study/NCT06161844) | Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 506 |
| [NCT06986993](https://clinicaltrials.gov/study/NCT06986993) | Impact of Semaglutide on Tobacco Use and Related Health Behaviors | Tobacco Use | Phase 4 | RECRUITING | 40 |
| [NCT05548647](https://clinicaltrials.gov/study/NCT05548647) | Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects | Obesity | Phase 4 | COMPLETED | 120 |
| [NCT03548987](https://clinicaltrials.gov/study/NCT03548987) | Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Metabolism and Nutrition Disorder, Obesity | Phase 3 | COMPLETED | 902 |
| [NCT07536516](https://clinicaltrials.gov/study/NCT07536516) | Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients | Diabetes Mellitus | Not phased | RECRUITING | 20 |
| [NCT05891587](https://clinicaltrials.gov/study/NCT05891587) | Semaglutide Therapy for Alcohol Reduction - Tulsa | Alcohol Use Disorder | Phase 2 | COMPLETED | 80 |
| [NCT06771115](https://clinicaltrials.gov/study/NCT06771115) | Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity | Obesity | Phase 2 | COMPLETED | 176 |
| [NCT05819138](https://clinicaltrials.gov/study/NCT05819138) | Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes | Diabetes Mellitus, Type 1 | Phase 3 | RECRUITING | 60 |
| [NCT07617155](https://clinicaltrials.gov/study/NCT07617155) | GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis | Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis | Phase 4 | NOT_YET_RECRUITING | 396 |
| [NCT05822609](https://clinicaltrials.gov/study/NCT05822609) | Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes | Diabetic Kidney Disease, Type 1 Diabetes | Phase 2 | RECRUITING | 60 |
| [NCT05352815](https://clinicaltrials.gov/study/NCT05352815) | A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1291 |
| [NCT05891496](https://clinicaltrials.gov/study/NCT05891496) | A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Alzheimers Disease | Phase 3 | COMPLETED | 23 |
| [NCT06792422](https://clinicaltrials.gov/study/NCT06792422) | A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma | Primary Open Angle Glaucoma (POAG), Open-Angle Glaucoma | Phase 4 | RECRUITING | 126 |
| [NCT03789578](https://clinicaltrials.gov/study/NCT03789578) | A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 30 |
| [NCT06852391](https://clinicaltrials.gov/study/NCT06852391) | JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity | Obesity (Disorder) | Phase 4 | RECRUITING | 74 |
| [NCT07223983](https://clinicaltrials.gov/study/NCT07223983) | Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) | Alcohol Use Disorder, Weight Loss | Phase 1 | RECRUITING | 10 |
| [NCT06613854](https://clinicaltrials.gov/study/NCT06613854) | Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Phase 4 | RECRUITING | 90 |
| [NCT07251556](https://clinicaltrials.gov/study/NCT07251556) | GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis | Psoriasis Arthritis | Phase 4 | NOT_YET_RECRUITING | 40 |
| [NCT03724981](https://clinicaltrials.gov/study/NCT03724981) | A Study Comparing the Dulaglutide Pen and the Semaglutide Pen | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 312 |
| [NCT06082063](https://clinicaltrials.gov/study/NCT06082063) | Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes | Cardiovascular Diseases, Heart Failure | Phase 3 | RECRUITING | 2000 |
| [NCT02970942](https://clinicaltrials.gov/study/NCT02970942) | Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. | Hepatobiliary Disorders, Non-alcoholic Steatohepatitis | Phase 2 | COMPLETED | 320 |
| [NCT07622810](https://clinicaltrials.gov/study/NCT07622810) | BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity | Obesity & Overweight | Phase 3 | NOT_YET_RECRUITING | 352 |
| [NCT05586802](https://clinicaltrials.gov/study/NCT05586802) | Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome | Klinefelter Syndrome | Phase 3 | RECRUITING | 150 |
| [NCT01272973](https://clinicaltrials.gov/study/NCT01272973) | Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 96 |
| [NCT06446531](https://clinicaltrials.gov/study/NCT06446531) | Prevention of Progression of Prediabetes, Obesity and CV Risk | Pre-Diabetes, Weight, Body | Phase 1 | RECRUITING | 64 |
| [NCT07728383](https://clinicaltrials.gov/study/NCT07728383) | A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity | Obesity & Overweight | Phase 4 | RECRUITING | 40 |
| [NCT07558863](https://clinicaltrials.gov/study/NCT07558863) | Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes | Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis) | Phase 4 | RECRUITING | 60 |
| [NCT04451837](https://clinicaltrials.gov/study/NCT04451837) | Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology | Type2 Diabetes | Phase 2 | ACTIVE_NOT_RECRUITING | 200 |
| [NCT05129891](https://clinicaltrials.gov/study/NCT05129891) | A Research Study Looking at New Protein-based Tablets in Healthy Male Participants | Healthy Volunteers, High Blood Cholesterol Levels | Phase 1 | COMPLETED | 384 |
| [NCT07653477](https://clinicaltrials.gov/study/NCT07653477) | Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) | Type 2 Diabetes | Phase 3 | NOT_YET_RECRUITING | 956 |
| [NCT04251156](https://clinicaltrials.gov/study/NCT04251156) | Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. | Overweight, Obesity | Phase 3 | COMPLETED | 375 |
| [NCT07017270](https://clinicaltrials.gov/study/NCT07017270) | Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis | Kidney Disease, Chronic, Diabetes | Phase 4 | RECRUITING | 100 |
| [NCT04979130](https://clinicaltrials.gov/study/NCT04979130) | Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB) | Type 2 Diabetes, Chronic Inflammation | Phase 4 | COMPLETED | 69 |
| [NCT07213323](https://clinicaltrials.gov/study/NCT07213323) | Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment | Obesity &Amp; Overweight, Digestive Disorders | Not phased | NOT_YET_RECRUITING | 50 |
| [NCT07227948](https://clinicaltrials.gov/study/NCT07227948) | Repurposing Semaglutide for the Treatment of Cocaine Use Disorder | Cocaine Use Disorder | Phase 2 | RECRUITING | 75 |
| [NCT05259033](https://clinicaltrials.gov/study/NCT05259033) | A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 683 |
| [NCT07204249](https://clinicaltrials.gov/study/NCT07204249) | Glutide for Ending Methamphetamine | Methamphetamine-dependence | Phase 2 | RECRUITING | 162 |
| [NCT02022254](https://clinicaltrials.gov/study/NCT02022254) | Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 24 |
| [NCT04238962](https://clinicaltrials.gov/study/NCT04238962) | A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens | Overweight, Obesity | Phase 1 | COMPLETED | 111 |
| [NCT06639464](https://clinicaltrials.gov/study/NCT06639464) | Semaglutide for Helping Opioid Recovery | Opioid Use Disorder | Phase 2 | RECRUITING | 46 |
| [NCT07213466](https://clinicaltrials.gov/study/NCT07213466) | Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder | Bipolar I Disorder, Bipolar II Disorder | Phase 4 | RECRUITING | 100 |
| [NCT02607865](https://clinicaltrials.gov/study/NCT02607865) | Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1864 |
| [NCT03989232](https://clinicaltrials.gov/study/NCT03989232) | A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 961 |
| [NCT02773381](https://clinicaltrials.gov/study/NCT02773381) | A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 15 |
| [NCT05700877](https://clinicaltrials.gov/study/NCT05700877) | Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes | Type 2 Diabetes, Cardiovascular Diseases | Phase 4 | RECRUITING | 7300 |
| [NCT02146079](https://clinicaltrials.gov/study/NCT02146079) | A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 44 |
| [NCT06699329](https://clinicaltrials.gov/study/NCT06699329) | A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) | Healthy | Phase 1 | COMPLETED | 38 |
| [NCT04865744](https://clinicaltrials.gov/study/NCT04865744) | The Effect of Semaglutide on Pituitary Function | Healthy | Phase 4 | COMPLETED | 10 |
| [NCT07027969](https://clinicaltrials.gov/study/NCT07027969) | Metabolic Surgery for Atrial Fibrillation Elimination | Atrial Fibrillation, Obesity and Obesity-related Medical Conditions | Phase 4 | NOT_YET_RECRUITING | 100 |
| [NCT07592546](https://clinicaltrials.gov/study/NCT07592546) | Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss | Class I/II Obesity | Phase 4 | NOT_YET_RECRUITING | 240 |
| [NCT06289504](https://clinicaltrials.gov/study/NCT06289504) | A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight | Obesity | Phase 1 | COMPLETED | 34 |
| [NCT04938388](https://clinicaltrials.gov/study/NCT04938388) | Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care | Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus) | Phase 4 | TERMINATED | 12 |
| [NCT07400107](https://clinicaltrials.gov/study/NCT07400107) | AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Obesity, Overweight | Phase 3 | NOT_YET_RECRUITING | 1000 |
| [NCT06184633](https://clinicaltrials.gov/study/NCT06184633) | DUTCH Weight Control in Atrial Fibrillation Study | Atrial Fibrillation, Obesity | Phase 4 | RECRUITING | 280 |
| [NCT05890976](https://clinicaltrials.gov/study/NCT05890976) | Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) | Overweight, Obesity | Phase 3 | COMPLETED | 200 |
| [NCT06780449](https://clinicaltrials.gov/study/NCT06780449) | A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 400 |
| [NCT03936660](https://clinicaltrials.gov/study/NCT03936660) | A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease | Diabetes Mellitus, Type 2, Cardiovascular Diseases | Not phased | COMPLETED | 1049 |
| [NCT02079870](https://clinicaltrials.gov/study/NCT02079870) | Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo | Diabetes, Metabolism and Nutrition Disorder | Phase 1 | COMPLETED | 30 |
| [NCT06894784](https://clinicaltrials.gov/study/NCT06894784) | A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | Diabetes Type 1 | Phase 3 | RECRUITING | 36 |
| [NCT07319975](https://clinicaltrials.gov/study/NCT07319975) | Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity | Obesity | Not phased | NOT_YET_RECRUITING | 48 |
| [NCT05394519](https://clinicaltrials.gov/study/NCT05394519) | A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight | Overweight, Obesity | Phase 3 | COMPLETED | 1200 |
| [NCT05857085](https://clinicaltrials.gov/study/NCT05857085) | Novel Therapeutics and Endothelial Dysfunction in T1DM Patients | Endothelial Dysfunction, Diabetes Mellitus, Type 1 | Phase 4 | COMPLETED | 90 |
| [NCT06555146](https://clinicaltrials.gov/study/NCT06555146) | Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy | Diabetes Mellitus, Type 2, Kidney Disease, Chronic | Not phased | NOT_YET_RECRUITING | 15 |
| [NCT04097600](https://clinicaltrials.gov/study/NCT04097600) | A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets | Healthy Volunteers, Type 2 Diabetes | Phase 1 | COMPLETED | 274 |
| [NCT04865770](https://clinicaltrials.gov/study/NCT04865770) | A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) | Diabetes Mellitus, Type 2, Chronic Kidney Disease | Phase 3 | COMPLETED | 106 |
| [NCT03136484](https://clinicaltrials.gov/study/NCT03136484) | Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 788 |
| [NCT05498610](https://clinicaltrials.gov/study/NCT05498610) | A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 24 |
| [NCT07610174](https://clinicaltrials.gov/study/NCT07610174) | Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves | Heart Failure, Heart Valve Prosthesis | Phase 2 | COMPLETED | 160 |
| [NCT07021937](https://clinicaltrials.gov/study/NCT07021937) | Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity | Obesity/Therapy | Phase 3 | NOT_YET_RECRUITING | 120 |
| [NCT07179120](https://clinicaltrials.gov/study/NCT07179120) | Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health | Obesity-related Male Infertility | Phase 2 | NOT_YET_RECRUITING | 180 |
| [NCT04971785](https://clinicaltrials.gov/study/NCT04971785) | Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 457 |
| [NCT07430059](https://clinicaltrials.gov/study/NCT07430059) | Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | Obesity & Overweight | Phase 1 | NOT_YET_RECRUITING | 20 |
| [NCT07677995](https://clinicaltrials.gov/study/NCT07677995) | Free Fatty Acid Effects In Type 2 Diabetes | Type 2 Diabetes, Cardiovascular Disease | Not phased | ENROLLING_BY_INVITATION | 60 |
| [NCT02692716](https://clinicaltrials.gov/study/NCT02692716) | A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 3183 |
| [NCT06619015](https://clinicaltrials.gov/study/NCT06619015) | Tailoring Obesity Treatment Trial | Obesity, Appetite Regulation | Phase 3 | WITHDRAWN | 0 |
| [NCT05333003](https://clinicaltrials.gov/study/NCT05333003) | Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity | Schizophrenia Spectrum Disorders | Not phased | ACTIVE_NOT_RECRUITING | 92 |
| [NCT07502508](https://clinicaltrials.gov/study/NCT07502508) | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy | Type 2 Diabetes | Phase 2 | RECRUITING | 60 |
| [NCT07223242](https://clinicaltrials.gov/study/NCT07223242) | Tailored Exercise Training Study Among Adults With HFpEF | HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies | Phase 3 | RECRUITING | 120 |
| [NCT07465965](https://clinicaltrials.gov/study/NCT07465965) | A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults | Overweight, Obesity | Phase 1 | RECRUITING | 60 |
| [NCT06648031](https://clinicaltrials.gov/study/NCT06648031) | Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | Type2diabetes | Phase 1 | COMPLETED | 148 |
| [NCT07107334](https://clinicaltrials.gov/study/NCT07107334) | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | Endometrioid Endometrial Adenocarcinoma | Phase 2 | RECRUITING | 20 |
| [NCT05779644](https://clinicaltrials.gov/study/NCT05779644) | Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus | Metformin, Obesity, Abdominal | Not phased | UNKNOWN | 300 |
| [NCT04143945](https://clinicaltrials.gov/study/NCT04143945) | A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity | Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight | Phase 2 | COMPLETED | 104 |
| [NCT06050577](https://clinicaltrials.gov/study/NCT06050577) | The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial | Type 2 Diabetes, Osteopenia | Phase 2 | ACTIVE_NOT_RECRUITING | 64 |
| [NCT07597018](https://clinicaltrials.gov/study/NCT07597018) | A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity | Obesity, Overweight | Phase 1 | RECRUITING | 234 |
| [NCT05501483](https://clinicaltrials.gov/study/NCT05501483) | Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes | Type 2 Diabetes | Not phased | RECRUITING | 60 |
| [NCT05254314](https://clinicaltrials.gov/study/NCT05254314) | Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) | Asthma | Phase 2 | ACTIVE_NOT_RECRUITING | 100 |
| [NCT06410352](https://clinicaltrials.gov/study/NCT06410352) | Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome | Metabolic Syndrome | Phase 4 | RECRUITING | 220 |
| [NCT05816057](https://clinicaltrials.gov/study/NCT05816057) | A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 476 |
| [NCT06361823](https://clinicaltrials.gov/study/NCT06361823) | Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment | Idiopathic Intracranial Hypertension | Phase 3 | UNKNOWN | 74 |
| [NCT06499857](https://clinicaltrials.gov/study/NCT06499857) | Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation | Overweight or Obesity, Atrial Fibrillation | Phase 3 | RECRUITING | 200 |
| [NCT04940078](https://clinicaltrials.gov/study/NCT04940078) | A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity | Obesity & Overweight | Phase 1 | COMPLETED | 40 |
| [NCT07357740](https://clinicaltrials.gov/study/NCT07357740) | A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | WITHDRAWN | 0 |
| [NCT07633639](https://clinicaltrials.gov/study/NCT07633639) | GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | Obesity | Not phased | RECRUITING | 200 |
| [NCT03919929](https://clinicaltrials.gov/study/NCT03919929) | Treating PCOS With Semaglutide vs Active Lifestyle Intervention | PCOS, Adolescent Obesity | Phase 3 | COMPLETED | 60 |
| [NCT07662213](https://clinicaltrials.gov/study/NCT07662213) | A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | Phase 3 | RECRUITING | 1200 |
| [NCT06715514](https://clinicaltrials.gov/study/NCT06715514) | Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes | Menopause, Type 2 Diabetes | Not phased | RECRUITING | 96 |
| [NCT07728669](https://clinicaltrials.gov/study/NCT07728669) | Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy | Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder) | Not phased | RECRUITING | 120 |
| [NCT06260722](https://clinicaltrials.gov/study/NCT06260722) | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Diabetes Mellitus, Type 2 | Phase 3 | ACTIVE_NOT_RECRUITING | 1250 |
| [NCT07539415](https://clinicaltrials.gov/study/NCT07539415) | A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers | Obesity & Overweight, Type 2 Diabetes | Phase 1 | RECRUITING | 72 |
| [NCT06390501](https://clinicaltrials.gov/study/NCT06390501) | The Effect of Weekly Semaglutide Treatment on Energy Expenditure | Obesity; Drug | Not phased | COMPLETED | 60 |
| [NCT04524832](https://clinicaltrials.gov/study/NCT04524832) | Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 290 |
| [NCT05078255](https://clinicaltrials.gov/study/NCT05078255) | The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes | Type 2 Diabetes, Obesity | Not phased | COMPLETED | 61 |
| [NCT04892199](https://clinicaltrials.gov/study/NCT04892199) | Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? | Metabolic Disturbance, Schizophrenia | Phase 4 | ACTIVE_NOT_RECRUITING | 104 |
| [NCT06734312](https://clinicaltrials.gov/study/NCT06734312) | MAINTAIN (Mucosal AblatIoN Therapy After INcretins) | Obesity and Obesity-related Medical Conditions, Obesity and Overweight | Not phased | RECRUITING | 20 |
| [NCT07389941](https://clinicaltrials.gov/study/NCT07389941) | Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation | Atrial Fibrillation (AF) | Phase 4 | NOT_YET_RECRUITING | 240 |
| [NCT02064348](https://clinicaltrials.gov/study/NCT02064348) | A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 168 |
| [NCT07724340](https://clinicaltrials.gov/study/NCT07724340) | A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity | Adults With Overweight/Obesity and Type 2 Diabetes | Phase 2 | RECRUITING | 150 |
| [NCT07411378](https://clinicaltrials.gov/study/NCT07411378) | Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. | Muscle Wasting, Obesity & Overweight | Phase 2 | NOT_YET_RECRUITING | 164 |
| [NCT05232708](https://clinicaltrials.gov/study/NCT05232708) | A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide | Healthy Volunteers (Diabetes Mellitus, Type 2) | Phase 1 | COMPLETED | 18 |
| [NCT07226947](https://clinicaltrials.gov/study/NCT07226947) | Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment | Obesity, Body Composition | Not phased | RECRUITING | 100 |
| [NCT06738979](https://clinicaltrials.gov/study/NCT06738979) | A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects | Obesity | Phase 3 | NOT_YET_RECRUITING | 408 |
| [NCT03061214](https://clinicaltrials.gov/study/NCT03061214) | Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 868 |
| [NCT06814938](https://clinicaltrials.gov/study/NCT06814938) | A Study of a Novel Precision Medicine Approach For Obesity | Obesity | Phase 4 | ACTIVE_NOT_RECRUITING | 135 |
| [NCT01866748](https://clinicaltrials.gov/study/NCT01866748) | Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 170 |
| [NCT06691243](https://clinicaltrials.gov/study/NCT06691243) | Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV | Cocaine Use Disorder, HIV | Phase 2 | RECRUITING | 40 |
| [NCT03951753](https://clinicaltrials.gov/study/NCT03951753) | A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 117 |
| [NCT07727473](https://clinicaltrials.gov/study/NCT07727473) | Preoperative Semaglutide Prior to Radical Prostatectomy | Prostate Cancer | Phase 1 | NOT_YET_RECRUITING | 20 |
| [NCT03086330](https://clinicaltrials.gov/study/NCT03086330) | Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 302 |
| [NCT04187300](https://clinicaltrials.gov/study/NCT04187300) | A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity | Overweight, Obesity | Phase 1 | COMPLETED | 68 |
| [NCT05579977](https://clinicaltrials.gov/study/NCT05579977) | Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity | Diabetes Mellitus, Obesity | Phase 2 | TERMINATED | 902 |
| [NCT07249554](https://clinicaltrials.gov/study/NCT07249554) | Combination Therapy for Alcohol Use Disorder | Alcohol Use Disorder | Phase 2 | NOT_YET_RECRUITING | 45 |
| [NCT07621640](https://clinicaltrials.gov/study/NCT07621640) | Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study) | Obesity, Metabolic Syndrome | Not phased | NOT_YET_RECRUITING | 80 |
| [NCT06215196](https://clinicaltrials.gov/study/NCT06215196) | Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity | Overweight and Obesity | Not phased | COMPLETED | 81 |
| [NCT07035704](https://clinicaltrials.gov/study/NCT07035704) | Prevent and Reverse Obesity in Children, Adolescents and Young Adults | Overweight (BMI > 25) | Not phased | NOT_YET_RECRUITING | 200 |
| [NCT05015894](https://clinicaltrials.gov/study/NCT05015894) | A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 42 |
| [NCT05870462](https://clinicaltrials.gov/study/NCT05870462) | Semaglutide and Vascular Regeneration | Atherosclerosis, Cardiovascular Diseases | Phase 4 | UNKNOWN | 100 |
| [NCT02557620](https://clinicaltrials.gov/study/NCT02557620) | Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly | Diabetes, Healthy | Phase 1 | COMPLETED | 113 |
| [NCT02070510](https://clinicaltrials.gov/study/NCT02070510) | A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 52 |
| [NCT05780905](https://clinicaltrials.gov/study/NCT05780905) | Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes | Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack | Phase 4 | RECRUITING | 50 |
| [NCT06041217](https://clinicaltrials.gov/study/NCT06041217) | A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range | Overweight, Obesity | Phase 3 | COMPLETED | 242 |
| [NCT05671653](https://clinicaltrials.gov/study/NCT05671653) | A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range | Obesity | Phase 1 | TERMINATED | 32 |
| [NCT04189848](https://clinicaltrials.gov/study/NCT04189848) | Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc | Healthy Volunteers, Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 104 |
| [NCT07096739](https://clinicaltrials.gov/study/NCT07096739) | Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1 | GLP-1 Concentration | Not phased | COMPLETED | 20 |
| [NCT04538352](https://clinicaltrials.gov/study/NCT04538352) | Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D | Type 2 Diabetes | Phase 4 | COMPLETED | 60 |
| [NCT07391267](https://clinicaltrials.gov/study/NCT07391267) | Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. | Chronic Kidney Diseases, MAFLD | Not phased | NOT_YET_RECRUITING | 90 |
| [NCT06745284](https://clinicaltrials.gov/study/NCT06745284) | A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity | Obesity | Phase 1 | ACTIVE_NOT_RECRUITING | 64 |
| [NCT05035095](https://clinicaltrials.gov/study/NCT05035095) | Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) | Obesity, Overweight | Phase 3 | COMPLETED | 667 |
| [NCT00696657](https://clinicaltrials.gov/study/NCT00696657) | A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 415 |
| [NCT07135245](https://clinicaltrials.gov/study/NCT07135245) | Improved Treatment and Monitoring of Alzheimer's Disease | Alzheimer Disease (AD) | Phase 2 | NOT_YET_RECRUITING | 180 |
| [NCT07701460](https://clinicaltrials.gov/study/NCT07701460) | Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1 | Weight Maintenance | Not phased | NOT_YET_RECRUITING | 200 |
| [NCT05356104](https://clinicaltrials.gov/study/NCT05356104) | GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) | Cerebral Small Vessel Disease | Phase 2 | RECRUITING | 110 |
| [NCT07336862](https://clinicaltrials.gov/study/NCT07336862) | Bariatric Surgery Combined With GLP-1 Receptor Agonists Study | Obesity | Phase 2 | RECRUITING | 200 |
| [NCT04032197](https://clinicaltrials.gov/study/NCT04032197) | A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 101 |
| [NCT06579105](https://clinicaltrials.gov/study/NCT06579105) | Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. | Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 406 |
| [NCT07202247](https://clinicaltrials.gov/study/NCT07202247) | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | RECRUITING | 60 |
| [NCT03689374](https://clinicaltrials.gov/study/NCT03689374) | A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 2274 |
| [NCT05616013](https://clinicaltrials.gov/study/NCT05616013) | Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Obesity, Obese | Phase 2 | COMPLETED | 507 |
| [NCT07087795](https://clinicaltrials.gov/study/NCT07087795) | A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes | Diabetes Mellitus, Type 1 | Phase 1 | ACTIVE_NOT_RECRUITING | 96 |
| [NCT07194317](https://clinicaltrials.gov/study/NCT07194317) | A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment | Obese Patients | Not phased | COMPLETED | 64 |
| [NCT05892432](https://clinicaltrials.gov/study/NCT05892432) | Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD) | Alcohol Use Disorder | Phase 2 | COMPLETED | 50 |
| [NCT06533527](https://clinicaltrials.gov/study/NCT06533527) | Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Diabetes Mellitus, Type 2, Obesity | Phase 4 | COMPLETED | 69 |
| [NCT06500429](https://clinicaltrials.gov/study/NCT06500429) | A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist | Overweight and Obesity, Healthy | Phase 2 | COMPLETED | 120 |
| [NCT02249871](https://clinicaltrials.gov/study/NCT02249871) | Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 54 |
| [NCT05766709](https://clinicaltrials.gov/study/NCT05766709) | A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations | Non-alcoholic Steatohepatitis | Phase 1 | COMPLETED | 53 |
| [NCT06629688](https://clinicaltrials.gov/study/NCT06629688) | Semaglutide and Intestinal Iron Absorption | Diabetes Mellitus Type 2, Iron Absorption | Not phased | COMPLETED | 51 |
| [NCT07150975](https://clinicaltrials.gov/study/NCT07150975) | Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | Obesity/Overweight in Adult | Phase 3 | RECRUITING | 420 |
| [NCT06903923](https://clinicaltrials.gov/study/NCT06903923) | Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy | Obesity in Children, Bone Strength | Phase 2 | RECRUITING | 120 |
| [NCT04969939](https://clinicaltrials.gov/study/NCT04969939) | A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity | Obesity | Phase 2 | COMPLETED | 120 |
| [NCT02863419](https://clinicaltrials.gov/study/NCT02863419) | Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 711 |
| [NCT07272343](https://clinicaltrials.gov/study/NCT07272343) | The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM), Semaglutide | Phase 4 | RECRUITING | 100 |
| [NCT05938712](https://clinicaltrials.gov/study/NCT05938712) | The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | Kidney Transplant Recipients | Phase 2 | RECRUITING | 20 |
| [NCT04515849](https://clinicaltrials.gov/study/NCT04515849) | A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus, Chronic Kidney Diseases | Phase 2 | COMPLETED | 248 |
| [NCT07478198](https://clinicaltrials.gov/study/NCT07478198) | Study on the Efficacy and Safety of PLLA Injections for Improving Facial Laxity Following GLP-1 Analog Therapy | Facial Skin Laxity | Not phased | ENROLLING_BY_INVITATION | 22 |
| [NCT06608433](https://clinicaltrials.gov/study/NCT06608433) | Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function | Healthy Volunteer Study, HPA | Not phased | COMPLETED | 22 |
| [NCT07244445](https://clinicaltrials.gov/study/NCT07244445) | Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy | Dietary Change, Obesity & Overweight | Not phased | RECRUITING | 108 |
| [NCT05486065](https://clinicaltrials.gov/study/NCT05486065) | A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight | Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 245 |
| [NCT07446439](https://clinicaltrials.gov/study/NCT07446439) | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | Nausea and Vomiting, Obesity | Phase 3 | RECRUITING | 280 |
| [NCT05788965](https://clinicaltrials.gov/study/NCT05788965) | Semaglutide in CFRD | Cystic Fibrosis, Cystic Fibrosis-related Diabetes | Phase 3 | COMPLETED | 8 |
| [NCT02254291](https://clinicaltrials.gov/study/NCT02254291) | A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 308 |
| [NCT07040592](https://clinicaltrials.gov/study/NCT07040592) | Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide | Alcohol Use Disorder (AUD), HIV | Phase 2 | RECRUITING | 30 |
| [NCT04702516](https://clinicaltrials.gov/study/NCT04702516) | The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture | Osteopenia | Phase 2 | UNKNOWN | 64 |
| [NCT07639021](https://clinicaltrials.gov/study/NCT07639021) | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Obesity | Phase 2 | RECRUITING | 230 |
| [NCT07254572](https://clinicaltrials.gov/study/NCT07254572) | Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes | Coronary Artery Disease, PreDiabetes | Phase 4 | RECRUITING | 300 |
| [NCT05195944](https://clinicaltrials.gov/study/NCT05195944) | Semaglutide vs Sitagliptin | Liver Transplant; Complications, Diabetes Mellitus | Phase 4 | ENROLLING_BY_INVITATION | 58 |
| [NCT04228354](https://clinicaltrials.gov/study/NCT04228354) | A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide | Healthy Volunteers, Overweight | Phase 1 | COMPLETED | 28 |
| [NCT05202353](https://clinicaltrials.gov/study/NCT05202353) | A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver | Obesity | Phase 1 | ACTIVE_NOT_RECRUITING | 29 |
| [NCT03611582](https://clinicaltrials.gov/study/NCT03611582) | Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program | Overweight, Obesity | Phase 3 | COMPLETED | 611 |
| [NCT05478252](https://clinicaltrials.gov/study/NCT05478252) | A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 388 |
| [NCT01686945](https://clinicaltrials.gov/study/NCT01686945) | Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 107 |
| [NCT05813912](https://clinicaltrials.gov/study/NCT05813912) | A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 148 |
| [NCT05520775](https://clinicaltrials.gov/study/NCT05520775) | Semaglutide for Alcohol Use Disorder | Alcohol Use Disorder, Cigarette Smoking | Phase 2 | COMPLETED | 48 |
| [NCT07581145](https://clinicaltrials.gov/study/NCT07581145) | Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients | Foot Ulcer Due to Type 2 Diabetes Mellitus | Phase 3 | RECRUITING | 52 |
| [NCT03811561](https://clinicaltrials.gov/study/NCT03811561) | A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | ACTIVE_NOT_RECRUITING | 1500 |
| [NCT06642584](https://clinicaltrials.gov/study/NCT06642584) | A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV | Healthy Volunteers Type 2 Diabetes | Phase 1 | COMPLETED | 90 |
| [NCT06959784](https://clinicaltrials.gov/study/NCT06959784) | Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | Diabetes Mellitus, Cardiovascular Diseases | Phase 4 | ENROLLING_BY_INVITATION | 142 |
| [NCT07010432](https://clinicaltrials.gov/study/NCT07010432) | The Role of the Amylin Analogue Cagrilintide in Bone Metabolism | Obesity | Phase 1 | RECRUITING | 144 |
| [NCT04779697](https://clinicaltrials.gov/study/NCT04779697) | GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight | Obesity | Phase 1 | COMPLETED | 96 |
| [NCT04982575](https://clinicaltrials.gov/study/NCT04982575) | Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 92 |
| [NCT06267092](https://clinicaltrials.gov/study/NCT06267092) | A Study of How CagriSema Works on Appetite in People With Excess Body Weight | Overweight, Obesity | Phase 1 | COMPLETED | 164 |
| [NCT05424003](https://clinicaltrials.gov/study/NCT05424003) | Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant | NAFLD | Phase 2 | RECRUITING | 50 |
| [NCT06863363](https://clinicaltrials.gov/study/NCT06863363) | PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults | Non-diabetic Obesity | Phase 4 | NOT_YET_RECRUITING | 212 |
| [NCT06388187](https://clinicaltrials.gov/study/NCT06388187) | A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight | Obesity | Phase 3 | COMPLETED | 300 |
| [NCT05786521](https://clinicaltrials.gov/study/NCT05786521) | Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults | Aging, Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 20 |
| [NCT04287179](https://clinicaltrials.gov/study/NCT04287179) | SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | WITHDRAWN | 0 |
| [NCT05897372](https://clinicaltrials.gov/study/NCT05897372) | Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study | Diabetic Kidney Disease | Phase 2 | TERMINATED | 1 |
| [NCT07200622](https://clinicaltrials.gov/study/NCT07200622) | Oral Semaglutide in Patients With Alzheimer's Disease | Alzheimer Disease | Phase 2 | NOT_YET_RECRUITING | 60 |
| [NCT04152915](https://clinicaltrials.gov/study/NCT04152915) | A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens | Healthy Volunteers, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 68 |
| [NCT05067621](https://clinicaltrials.gov/study/NCT05067621) | Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | Phase 2 | ACTIVE_NOT_RECRUITING | 60 |
| [NCT06057077](https://clinicaltrials.gov/study/NCT06057077) | Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus | Type 1 Diabetes | Phase 2 | UNKNOWN | 120 |
| [NCT05537233](https://clinicaltrials.gov/study/NCT05537233) | ADJUnct Semaglutide Treatment in Type 1 Diabetes | Type 1 Diabetes, Obesity | Phase 2 | COMPLETED | 115 |
| [NCT05702931](https://clinicaltrials.gov/study/NCT05702931) | Semaglutide Treatment for Hyperglycaemia After Renal Transplantation | Hyperglycemia, Renal Transplant Complication Primary Non-Function | Phase 4 | RECRUITING | 104 |
| [NCT03288740](https://clinicaltrials.gov/study/NCT03288740) | A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 36 |
| [NCT06423599](https://clinicaltrials.gov/study/NCT06423599) | Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure | Heart Failure With Reduced Ejection Fraction, Obesity | Phase 3 | RECRUITING | 100 |
| [NCT07523633](https://clinicaltrials.gov/study/NCT07523633) | Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder | Cannabis Use Disorder, Cannabis Use Disorders | Phase 2 | RECRUITING | 100 |
| [NCT05819853](https://clinicaltrials.gov/study/NCT05819853) | Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese | Phase 3 | RECRUITING | 80 |
| [NCT06897475](https://clinicaltrials.gov/study/NCT06897475) | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Type 2 Diabetes | Phase 2 | RECRUITING | 240 |
| [NCT02920385](https://clinicaltrials.gov/study/NCT02920385) | A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects. | Diabetes, Healthy | Phase 1 | COMPLETED | 45 |
| [NCT06655740](https://clinicaltrials.gov/study/NCT06655740) | Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes | Diabetes Mellitus, Type 2 | Not phased | ACTIVE_NOT_RECRUITING | 16 |
| [NCT06005012](https://clinicaltrials.gov/study/NCT06005012) | Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM | Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese | Phase 2 | ACTIVE_NOT_RECRUITING | 120 |
| [NCT03596450](https://clinicaltrials.gov/study/NCT03596450) | Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 1278 |
| [NCT06497049](https://clinicaltrials.gov/study/NCT06497049) | Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®. | Pharmacokinetics, Safety Issues | Phase 1 | COMPLETED | 120 |
| [NCT06706284](https://clinicaltrials.gov/study/NCT06706284) | Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes | Spinal Cord Injuries, Type 2 Diabetes | Phase 4 | RECRUITING | 50 |
| [NCT07172867](https://clinicaltrials.gov/study/NCT07172867) | A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM | Diabetes Mellitus, Type 2, Obesity | Phase 2 | WITHDRAWN | 0 |
| [NCT04998136](https://clinicaltrials.gov/study/NCT04998136) | Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Obesity | Phase 3 | COMPLETED | 150 |
| [NCT06830343](https://clinicaltrials.gov/study/NCT06830343) | The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity | Overweight or Obesity | Phase 1 | RECRUITING | 66 |
| [NCT06633783](https://clinicaltrials.gov/study/NCT06633783) | A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® | Obesity | Phase 3 | NOT_YET_RECRUITING | 370 |
| [NCT03292315](https://clinicaltrials.gov/study/NCT03292315) | Once Weekly GLP-1 in Persons With Spinal Cord Injury | Spinal Cord Injuries, Insulin Resistance | Phase 4 | COMPLETED | 5 |
| [NCT06339086](https://clinicaltrials.gov/study/NCT06339086) | Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 3 | UNKNOWN | 478 |
| [NCT05646199](https://clinicaltrials.gov/study/NCT05646199) | Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) | Polycystic Ovary Syndrome | Phase 3 | UNKNOWN | 60 |
| [NCT06069895](https://clinicaltrials.gov/study/NCT06069895) | Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants | Healthy Participants | Phase 1 | COMPLETED | 170 |
| [NCT03842202](https://clinicaltrials.gov/study/NCT03842202) | A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity | Overweight, Obesity | Phase 1 | COMPLETED | 72 |
| [NCT04074161](https://clinicaltrials.gov/study/NCT04074161) | Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity | Overweight, Obesity | Phase 3 | COMPLETED | 338 |
| [NCT00851773](https://clinicaltrials.gov/study/NCT00851773) | Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 84 |
| [NCT04513704](https://clinicaltrials.gov/study/NCT04513704) | A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times | Healthy Volunteers Type 2 Diabetes | Phase 1 | COMPLETED | 156 |
| [NCT07282769](https://clinicaltrials.gov/study/NCT07282769) | Semaglutide (Wegovy) Treatment for Trichotillomania | Trichotillomania (Hair-Pulling Disorder), Trichotillomania | Phase 2 | NOT_YET_RECRUITING | 10 |
| [NCT04615871](https://clinicaltrials.gov/study/NCT04615871) | Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 | Covid19, Myocardial Injury | Phase 2 | UNKNOWN | 400 |
| [NCT06207877](https://clinicaltrials.gov/study/NCT06207877) | A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight | Obesity | Phase 1 | COMPLETED | 62 |
| [NCT07599046](https://clinicaltrials.gov/study/NCT07599046) | Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes | Obesity Type 2 Diabetes Mellitus | Not phased | NOT_YET_RECRUITING | 20 |
| [NCT04624672](https://clinicaltrials.gov/study/NCT04624672) | Treatment of GLP-1 for Diabetic Bariatric Patients | Diabetes Mellitus, Type 2 | Phase 4 | TERMINATED | 3 |
| [NCT05071417](https://clinicaltrials.gov/study/NCT05071417) | Effect Of Semaglutide In Coronary Atheroma Plaque | Atheroscleroses, Coronary | Phase 3 | UNKNOWN | 120 |
| [NCT07101939](https://clinicaltrials.gov/study/NCT07101939) | A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) | Obesity, Muscle Loss | Phase 2 | RECRUITING | 120 |
| [NCT05205928](https://clinicaltrials.gov/study/NCT05205928) | Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care | Type 1 Diabetes, Diabetes Mellitus, Type 1 | Phase 3 | COMPLETED | 28 |
| [NCT04944992](https://clinicaltrials.gov/study/NCT04944992) | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 145 |
| [NCT03987919](https://clinicaltrials.gov/study/NCT03987919) | A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | COMPLETED | 1879 |
| [NCT07297589](https://clinicaltrials.gov/study/NCT07297589) | Epicardial Cardiac Fat-CT (EPIC-CT) | STEMI - ST Elevation Myocardial Infarction, Epicardial Fat | Phase 3 | RECRUITING | 136 |
| [NCT02212067](https://clinicaltrials.gov/study/NCT02212067) | A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 87 |
| [NCT02147431](https://clinicaltrials.gov/study/NCT02147431) | A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 38 |
| [NCT04466345](https://clinicaltrials.gov/study/NCT04466345) | Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder | Major Depressive Disorder | Phase 2 | COMPLETED | 72 |
| [NCT06003153](https://clinicaltrials.gov/study/NCT06003153) | GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH | Genetic Predisposition, Metabolic Diseases | Phase 4 | RECRUITING | 125 |
| [NCT06640972](https://clinicaltrials.gov/study/NCT06640972) | Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists | Triglycerides, Weight Gain Trajectory | Phase 2 | COMPLETED | 68 |
| [NCT05227196](https://clinicaltrials.gov/study/NCT05227196) | A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People | Healthy Volunteers, Type 2 Diabetes | Phase 1 | COMPLETED | 546 |
| [NCT06575738](https://clinicaltrials.gov/study/NCT06575738) | Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents | Obesity, Adolescent Obesity | Phase 1 | RECRUITING | 40 |
| [NCT07092618](https://clinicaltrials.gov/study/NCT07092618) | Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation | Longevity, GLP-1 | Phase 3 | RECRUITING | 150 |
| [NCT04102189](https://clinicaltrials.gov/study/NCT04102189) | A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Overweight, Obesity | Phase 3 | COMPLETED | 201 |
| [NCT05702905](https://clinicaltrials.gov/study/NCT05702905) | Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome | PCOS (Polycystic Ovary Syndrome), Semaglutide | Phase 4 | UNKNOWN | 75 |
| [NCT04447859](https://clinicaltrials.gov/study/NCT04447859) | 16-week Flexible vs. 8-week Semaglutide Titration | Diabetes type2 | Phase 3 | UNKNOWN | 100 |
| [NCT05236517](https://clinicaltrials.gov/study/NCT05236517) | A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity | Obesity | Phase 1 | COMPLETED | 60 |
| [NCT06097390](https://clinicaltrials.gov/study/NCT06097390) | A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III | Healthy Participants | Phase 1 | COMPLETED | 121 |
| [NCT06989177](https://clinicaltrials.gov/study/NCT06989177) | Probiotic Intervention on Body Weight | Obesity, Homeostasis | Not phased | RECRUITING | 140 |
| [NCT06982859](https://clinicaltrials.gov/study/NCT06982859) | A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Insulin Sensitivity | Phase 1 | ACTIVE_NOT_RECRUITING | 95 |
| [NCT03018028](https://clinicaltrials.gov/study/NCT03018028) | Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 243 |
| [NCT06221969](https://clinicaltrials.gov/study/NCT06221969) | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Type 2 Diabetes | Phase 3 | COMPLETED | 1024 |
| [NCT06803888](https://clinicaltrials.gov/study/NCT06803888) | Bariatric Surgery vs. Semaglutide vs. Tirzepatide | Obesity and Obesity-related Medical Conditions | Phase 4 | ACTIVE_NOT_RECRUITING | 125 |
| [NCT04707469](https://clinicaltrials.gov/study/NCT04707469) | Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1606 |
| [NCT04012255](https://clinicaltrials.gov/study/NCT04012255) | A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity | Overweight, Obesity | Phase 1 | TERMINATED | 29 |
| [NCT05670379](https://clinicaltrials.gov/study/NCT05670379) | Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant | Overweight and Obesity, Type2diabetes | Phase 1 | COMPLETED | 24 |
| [NCT05429593](https://clinicaltrials.gov/study/NCT05429593) | A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet | Healthy Volunteers | Phase 1 | COMPLETED | 152 |
| [NCT01720446](https://clinicaltrials.gov/study/NCT01720446) | Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 3297 |
| [NCT04017832](https://clinicaltrials.gov/study/NCT04017832) | A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1441 |
| [NCT06222437](https://clinicaltrials.gov/study/NCT06222437) | Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy | Polycystic Ovary Syndrome | Phase 1 | WITHDRAWN | 0 |
| [NCT07178145](https://clinicaltrials.gov/study/NCT07178145) | Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction | Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue | Phase 4 | RECRUITING | 192 |
| [NCT05564117](https://clinicaltrials.gov/study/NCT05564117) | Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range | Overweight, Obesity | Phase 3 | COMPLETED | 307 |
| [NCT04854083](https://clinicaltrials.gov/study/NCT04854083) | Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes | Type2 Diabetes | Phase 4 | UNKNOWN | 50 |
| [NCT07282613](https://clinicaltrials.gov/study/NCT07282613) | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 3 | NOT_YET_RECRUITING | 80 |
| [NCT04016974](https://clinicaltrials.gov/study/NCT04016974) | A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese | Healthy Volunteers, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 32 |
| [NCT06403761](https://clinicaltrials.gov/study/NCT06403761) | Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 158 |
| [NCT06132477](https://clinicaltrials.gov/study/NCT06132477) | Impact GLP-1 Agonists Following Bariatric | Morbid Obesity, Metabolic Syndrome | Phase 4 | RECRUITING | 150 |
| [NCT06717698](https://clinicaltrials.gov/study/NCT06717698) | A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Chronic Kidney Disease | Phase 2 | RECRUITING | 465 |
| [NCT06751589](https://clinicaltrials.gov/study/NCT06751589) | A Study of a Weight Loss Intervention in People With Endometrial Cancer | Endometrial Cancer | Phase 1 | RECRUITING | 36 |
| [NCT06363747](https://clinicaltrials.gov/study/NCT06363747) | The Medically Reproducing Bariatric Surgery (MRB) II Study | Type 2 Diabetes, Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 50 |
| [NCT05153564](https://clinicaltrials.gov/study/NCT05153564) | A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 27 |
| [NCT07221214](https://clinicaltrials.gov/study/NCT07221214) | GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV | HIV, Alcohol | Phase 2 | RECRUITING | 200 |
| [NCT04889183](https://clinicaltrials.gov/study/NCT04889183) | SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes | Obesity, Albuminuria | Phase 3 | COMPLETED | 125 |
| [NCT07368855](https://clinicaltrials.gov/study/NCT07368855) | GLP-1 Medicines and Mental Health Changes | Obesity, Depression | Not phased | COMPLETED | 90 |
| [NCT05119179](https://clinicaltrials.gov/study/NCT05119179) | Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes | PreDiabetes | Phase 4 | RECRUITING | 300 |
| [NCT06323174](https://clinicaltrials.gov/study/NCT06323174) | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | Type 2 Diabetes | Phase 3 | COMPLETED | 189 |
| [NCT06649344](https://clinicaltrials.gov/study/NCT06649344) | A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | ACTIVE_NOT_RECRUITING | 884 |
| [NCT07527195](https://clinicaltrials.gov/study/NCT07527195) | Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) | Obesity | Phase 1 | RECRUITING | 100 |
| [NCT06282458](https://clinicaltrials.gov/study/NCT06282458) | Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt | Muscle Loss, Obesity | Phase 2 | COMPLETED | 168 |
| [NCT05303857](https://clinicaltrials.gov/study/NCT05303857) | Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 107 |
| [NCT05144984](https://clinicaltrials.gov/study/NCT05144984) | A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 500 |
| [NCT07589322](https://clinicaltrials.gov/study/NCT07589322) | Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | Obesity and Metabolic Syndrome | Not phased | RECRUITING | 120 |
| [NCT03357380](https://clinicaltrials.gov/study/NCT03357380) | A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver | Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease | Phase 1 | COMPLETED | 67 |
| [NCT05435677](https://clinicaltrials.gov/study/NCT05435677) | A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 20 |
| [NCT03638778](https://clinicaltrials.gov/study/NCT03638778) | Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 105 |
| [NCT07539584](https://clinicaltrials.gov/study/NCT07539584) | Adiponectin in Patients With Metabolic Disorders | Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM) | Not phased | COMPLETED | 130 |
| [NCT06972992](https://clinicaltrials.gov/study/NCT06972992) | A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide | Chronic Weight Management | Phase 1 | COMPLETED | 28 |
| [NCT05996874](https://clinicaltrials.gov/study/NCT05996874) | A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants | Healthy Participants | Phase 1 | COMPLETED | 121 |
| [NCT05606471](https://clinicaltrials.gov/study/NCT05606471) | Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets | Type 2 Diabetes Mellitus in Obese | Phase 4 | UNKNOWN | 45 |
| [NCT07057310](https://clinicaltrials.gov/study/NCT07057310) | Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Obesity, Menopause | Phase 4 | ENROLLING_BY_INVITATION | 30 |
| [NCT00813020](https://clinicaltrials.gov/study/NCT00813020) | A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 44 |
| [NCT05064735](https://clinicaltrials.gov/study/NCT05064735) | Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis | Obesity | Phase 3 | COMPLETED | 407 |
| [NCT03598621](https://clinicaltrials.gov/study/NCT03598621) | A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 68 |
| [NCT05046873](https://clinicaltrials.gov/study/NCT05046873) | A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 16 |
| [NCT06937060](https://clinicaltrials.gov/study/NCT06937060) | Effect of Semaglutide in Patients With Psoriasis and Obesity | Psoriasis (PsO), Obesity and Overweight | Phase 3 | RECRUITING | 14 |
| [NCT05340868](https://clinicaltrials.gov/study/NCT05340868) | Genetics of the Acute Response to Oral Semaglutide | PreDiabetes, Prediabetic State | Not phased | RECRUITING | 1000 |
| [NCT07165158](https://clinicaltrials.gov/study/NCT07165158) | The Effect of Semaglutide on Bone Health | Osteoporosis, Osteoporosis Fracture | Phase 4 | NOT_YET_RECRUITING | 150 |
| [NCT07314528](https://clinicaltrials.gov/study/NCT07314528) | Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer | Rectal Cancer Patients, Obesity &Amp; Overweight | Phase 2 | NOT_YET_RECRUITING | 42 |
| [NCT04873050](https://clinicaltrials.gov/study/NCT04873050) | Treatment to Regress to Normoglycemia in Women with a Recent History of GDM | Pre Diabetes, Postpartum Disorder | Phase 4 | RECRUITING | 102 |
| [NCT06571383](https://clinicaltrials.gov/study/NCT06571383) | STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss | Obesity | Phase 4 | ACTIVE_NOT_RECRUITING | 500 |
| [NCT07563699](https://clinicaltrials.gov/study/NCT07563699) | Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus | Diabete Type 2 | Phase 2 | NOT_YET_RECRUITING | 24 |
| [NCT05616052](https://clinicaltrials.gov/study/NCT05616052) | Comparison of Body Weight Change Through Different Smeglutide Administration Methods | Weight Change, Body | Phase 4 | UNKNOWN | 80 |
| [NCT02172313](https://clinicaltrials.gov/study/NCT02172313) | Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 78 |
| [NCT07275697](https://clinicaltrials.gov/study/NCT07275697) | Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study | Atrial Fibrillation (AF), Obesity & Overweight | Phase 4 | NOT_YET_RECRUITING | 200 |
| [NCT05689099](https://clinicaltrials.gov/study/NCT05689099) | A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose | Diabetes Mellitus, Type 2, Healthy Participants | Phase 1 | COMPLETED | 20 |
| [NCT06065540](https://clinicaltrials.gov/study/NCT06065540) | A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 2734 |
| [NCT06422624](https://clinicaltrials.gov/study/NCT06422624) | A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects | Diabetes Mellitus, Type 2 | Phase 1 | UNKNOWN | 14 |
| [NCT03987451](https://clinicaltrials.gov/study/NCT03987451) | A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage | Non-alcoholic Steatohepatitis | Phase 2 | COMPLETED | 71 |
| [NCT06489457](https://clinicaltrials.gov/study/NCT06489457) | The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity | Type 2 Diabetes Mellitus, Obesity | Phase 3 | COMPLETED | 25 |
| [NCT04135287](https://clinicaltrials.gov/study/NCT04135287) | Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients | Diabetes Mellitus, Type 2 | Phase 4 | UNKNOWN | 315 |
| [NCT05442450](https://clinicaltrials.gov/study/NCT05442450) | Efficacy of Oral Semaglutide in Overweight or Obesity | Obesity, Weight Loss | Phase 4 | UNKNOWN | 116 |
| [NCT02054897](https://clinicaltrials.gov/study/NCT02054897) | Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 388 |
| [NCT06184568](https://clinicaltrials.gov/study/NCT06184568) | A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity | Type 2 Diabetes, Obesity | Phase 3 | COMPLETED | 349 |
| [NCT04777409](https://clinicaltrials.gov/study/NCT04777409) | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Early Alzheimer´s Disease | Phase 3 | COMPLETED | 1840 |
| [NCT07225816](https://clinicaltrials.gov/study/NCT07225816) | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | Obesity | Phase 1 | RECRUITING | 71 |
| [NCT07285902](https://clinicaltrials.gov/study/NCT07285902) | A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 572 |
| [NCT04174755](https://clinicaltrials.gov/study/NCT04174755) | Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV | Obesity, HIV-1-infection | Not phased | RECRUITING | 80 |
| [NCT05035082](https://clinicaltrials.gov/study/NCT05035082) | A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE) | Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 1020 |
| [NCT04788511](https://clinicaltrials.gov/study/NCT04788511) | Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity | Obesity | Phase 3 | COMPLETED | 529 |
| [NCT04153929](https://clinicaltrials.gov/study/NCT04153929) | A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. | Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 413 |
| [NCT02249910](https://clinicaltrials.gov/study/NCT02249910) | Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 32 |
| [NCT06323161](https://clinicaltrials.gov/study/NCT06323161) | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin | Type 2 Diabetes | Phase 3 | COMPLETED | 274 |
| [NCT07509112](https://clinicaltrials.gov/study/NCT07509112) | Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study | Methamphetamine Use Disorder | Phase 2 | NOT_YET_RECRUITING | 40 |
| [NCT05305794](https://clinicaltrials.gov/study/NCT05305794) | Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes" | Double Diabetes | Phase 3 | RECRUITING | 76 |
| [NCT06492330](https://clinicaltrials.gov/study/NCT06492330) | Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM | Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity | Not phased | COMPLETED | 62 |
| [NCT04885634](https://clinicaltrials.gov/study/NCT04885634) | Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients | Atrial Fibrillation, Overweight and Obesity | Phase 3 | WITHDRAWN | 0 |
| [NCT06577090](https://clinicaltrials.gov/study/NCT06577090) | Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo | Obesity | Phase 2 | ACTIVE_NOT_RECRUITING | 136 |
| [NCT07090343](https://clinicaltrials.gov/study/NCT07090343) | Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement | Aortic Stenosis, Heart Failure | Phase 3 | NOT_YET_RECRUITING | 826 |
| [NCT06605703](https://clinicaltrials.gov/study/NCT06605703) | A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) | Obesity, Overweight | Phase 4 | COMPLETED | 226 |
| [NCT05087342](https://clinicaltrials.gov/study/NCT05087342) | Latino Semaglutide Study | Obesity, Obesity; Drug | Phase 3 | COMPLETED | 119 |
| [NCT07036172](https://clinicaltrials.gov/study/NCT07036172) | Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients | Obesity Control | Phase 3 | RECRUITING | 460 |
| [NCT06497595](https://clinicaltrials.gov/study/NCT06497595) | Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide | Type 2 Diabetes Mellitus in Obese | Not phased | RECRUITING | 60 |
| [NCT07613437](https://clinicaltrials.gov/study/NCT07613437) | GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial | Intracerebral Hemorrhage | Phase 2 | NOT_YET_RECRUITING | 200 |
| [NCT02877355](https://clinicaltrials.gov/study/NCT02877355) | Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 55 |
| [NCT07295223](https://clinicaltrials.gov/study/NCT07295223) | Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) | Acute Myocardial Infarction With ST Elevation | Phase 3 | RECRUITING | 44 |
| [NCT05597202](https://clinicaltrials.gov/study/NCT05597202) | Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes | Type 2 Diabetes | Phase 4 | UNKNOWN | 22 |
| [NCT05990374](https://clinicaltrials.gov/study/NCT05990374) | Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years | Diabetes | Not phased | UNKNOWN | 100 |
| [NCT07364175](https://clinicaltrials.gov/study/NCT07364175) | A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults | Hypertension, Obesity & Overweight | Not phased | RECRUITING | 60 |
| [NCT03611322](https://clinicaltrials.gov/study/NCT03611322) | A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector) | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 54 |
| [NCT05726227](https://clinicaltrials.gov/study/NCT05726227) | A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 210 |
| [NCT06015893](https://clinicaltrials.gov/study/NCT06015893) | Semaglutide Therapy for Alcohol Reduction (STAR) | Addiction, Alcohol Use Disorder | Phase 2 | ACTIVE_NOT_RECRUITING | 63 |
| [NCT05950516](https://clinicaltrials.gov/study/NCT05950516) | Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | UNKNOWN | 478 |
| [NCT05649137](https://clinicaltrials.gov/study/NCT05649137) | A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Obesity, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 512 |
| [NCT03574584](https://clinicaltrials.gov/study/NCT03574584) | A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese | Metabolism and Nutrition Disorders, Overweight or Obesity | Phase 1 | COMPLETED | 37 |
| [NCT02231684](https://clinicaltrials.gov/study/NCT02231684) | Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide | Diabetes, Healthy | Phase 1 | COMPLETED | 42 |
| [NCT03498001](https://clinicaltrials.gov/study/NCT03498001) | Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging | Type II Diabetes | Not phased | COMPLETED | 42 |
| [NCT04383197](https://clinicaltrials.gov/study/NCT04383197) | Exercise and GLP-1 RA on Insulin Secretion | Type 2 Diabetes | Not phased | UNKNOWN | 30 |
| [NCT06788626](https://clinicaltrials.gov/study/NCT06788626) | Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment | Acute Ischemic Stroke, Large Vessel Occlusion | Phase 3 | NOT_YET_RECRUITING | 390 |
| [NCT07046273](https://clinicaltrials.gov/study/NCT07046273) | Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes | Type 2 Diabetes (T2DM) | Phase 3 | NOT_YET_RECRUITING | 496 |
| [NCT03659682](https://clinicaltrials.gov/study/NCT03659682) | GLP1R in Parkinson's Disease | Parkinson Disease | Phase 2 | UNKNOWN | 120 |
| [NCT02863328](https://clinicaltrials.gov/study/NCT02863328) | Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 822 |
| [NCT03884075](https://clinicaltrials.gov/study/NCT03884075) | Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) | Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease | Phase 2 | RECRUITING | 104 |
| [NCT06854614](https://clinicaltrials.gov/study/NCT06854614) | Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) | Obesity | Phase 4 | ACTIVE_NOT_RECRUITING | 150 |
| [NCT06884293](https://clinicaltrials.gov/study/NCT06884293) | A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） | Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Phase 3 | ACTIVE_NOT_RECRUITING | 479 |
| [NCT02207374](https://clinicaltrials.gov/study/NCT02207374) | A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 601 |
| [NCT05147896](https://clinicaltrials.gov/study/NCT05147896) | Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients | Diabetes Mellitus, Type 2, Atherosclerosis | Not phased | UNKNOWN | 100 |
| [NCT02461589](https://clinicaltrials.gov/study/NCT02461589) | Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes | Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 706 |
| [NCT05574439](https://clinicaltrials.gov/study/NCT05574439) | Young Adults With Early-onset Obesity Treated With Semaglutide | Obesity, Adolescent | Phase 4 | COMPLETED | 246 |
| [NCT07614412](https://clinicaltrials.gov/study/NCT07614412) | SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. | Type 1 Diabetes Mellitus | Phase 2 | NOT_YET_RECRUITING | 240 |
| [NCT05249881](https://clinicaltrials.gov/study/NCT05249881) | "Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan." | Diabetes Mellitus, Type 2, Weight Change, Body | Phase 1 | UNKNOWN | 300 |
| [NCT07511543](https://clinicaltrials.gov/study/NCT07511543) | Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy | Ischemic Stroke | Phase 3 | NOT_YET_RECRUITING | 826 |
| [NCT06411210](https://clinicaltrials.gov/study/NCT06411210) | Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment | Diabetes type1, Obesity | Phase 2 | RECRUITING | 54 |
| [NCT05193578](https://clinicaltrials.gov/study/NCT05193578) | Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes | Schizophrenia, Prediabetic State | Phase 2 | COMPLETED | 154 |
| [NCT03985384](https://clinicaltrials.gov/study/NCT03985384) | Semaglutide Treatment On Coronary Progression | Type 2 Diabetes, Coronary Artery Disease | Phase 4 | COMPLETED | 140 |
| [NCT02849080](https://clinicaltrials.gov/study/NCT02849080) | Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. | Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 504 |
| [NCT07374328](https://clinicaltrials.gov/study/NCT07374328) | Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus | Type 2 Diabetes | Phase 2 | RECRUITING | 240 |
| [NCT06060392](https://clinicaltrials.gov/study/NCT06060392) | Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus | Liver Transplant; Complications, Diabete Mellitus | Not phased | RECRUITING | 50 |
| [NCT05530577](https://clinicaltrials.gov/study/NCT05530577) | Effects of Semaglutide on Nicotine Intake | Tobacco Use Disorder, Nicotine Addiction | Phase 2 | COMPLETED | 24 |
| [NCT06299098](https://clinicaltrials.gov/study/NCT06299098) | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | Obesity | Phase 2 | ACTIVE_NOT_RECRUITING | 1005 |
| [NCT04822181](https://clinicaltrials.gov/study/NCT04822181) | Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Non-alcoholic Steatohepatitis | Phase 3 | ACTIVE_NOT_RECRUITING | 1205 |
| [NCT05746039](https://clinicaltrials.gov/study/NCT05746039) | Feasibility of Semaglutide in Advanced Lung Disease | Obesity, Interstitial Lung Disease | Phase 2 | RECRUITING | 8 |
| [NCT04741074](https://clinicaltrials.gov/study/NCT04741074) | Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy | CKD, Diabetic Kidney Disease | Phase 3 | TERMINATED | 15 |
| [NCT06338553](https://clinicaltrials.gov/study/NCT06338553) | GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab | Type 1 Diabetes | Phase 1 | RECRUITING | 24 |
| [NCT04777396](https://clinicaltrials.gov/study/NCT04777396) | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Early Alzheimer's Disease | Phase 3 | COMPLETED | 1840 |
| [NCT04873245](https://clinicaltrials.gov/study/NCT04873245) | Lifestyle Counseling and Medication for Adolescent Weight Management | Obesity, Childhood | Phase 2 | COMPLETED | 120 |
| [NCT06487832](https://clinicaltrials.gov/study/NCT06487832) | Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness | Normal Weight, Overweight and Obesity | Not phased | RECRUITING | 60 |
| [NCT06221696](https://clinicaltrials.gov/study/NCT06221696) | Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways) | Overweight and Obesity | Not phased | COMPLETED | 160 |
| [NCT05016882](https://clinicaltrials.gov/study/NCT05016882) | Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) | Non-alcoholic Steatohepatitis | Phase 2 | COMPLETED | 698 |
| [NCT07139548](https://clinicaltrials.gov/study/NCT07139548) | A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes | T2DM | Phase 3 | NOT_YET_RECRUITING | 600 |
| [NCT07627191](https://clinicaltrials.gov/study/NCT07627191) | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | Pancreatic Cancer, Colorectal Cancer | Phase 1 | NOT_YET_RECRUITING | 30 |
| [NCT06825793](https://clinicaltrials.gov/study/NCT06825793) | Semaglutide's Weight Loss Effects in Obesity | Obesity | Not phased | NOT_YET_RECRUITING | 56 |
| [NCT06243536](https://clinicaltrials.gov/study/NCT06243536) | The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients | Type 2 Diabetes, Overweight | Phase 4 | UNKNOWN | 60 |
| [NCT05669755](https://clinicaltrials.gov/study/NCT05669755) | REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | Cardiovascular Disease | Phase 3 | ACTIVE_NOT_RECRUITING | 7101 |
| [NCT02060266](https://clinicaltrials.gov/study/NCT02060266) | Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 7 |
| [NCT02210871](https://clinicaltrials.gov/study/NCT02210871) | Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 44 |
| [NCT05877547](https://clinicaltrials.gov/study/NCT05877547) | A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 2 | COMPLETED | 381 |
| [NCT06256549](https://clinicaltrials.gov/study/NCT06256549) | A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes | Phase 2 | UNKNOWN | 272 |
| [NCT05013229](https://clinicaltrials.gov/study/NCT05013229) | A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 679 |
| [NCT02845219](https://clinicaltrials.gov/study/NCT02845219) | A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females | Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 25 |
| [NCT07030621](https://clinicaltrials.gov/study/NCT07030621) | Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial | Acute Ischemic Stroke | Phase 3 | NOT_YET_RECRUITING | 436 |
| [NCT07392151](https://clinicaltrials.gov/study/NCT07392151) | Reversal to Normoglycemia by Treating Prediabetes | Prediabetes, Chronic Coronary Syndrome | Phase 3 | NOT_YET_RECRUITING | 158 |
| [NCT03574597](https://clinicaltrials.gov/study/NCT03574597) | Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | Overweight, Obesity | Phase 3 | COMPLETED | 17604 |
| [NCT07314684](https://clinicaltrials.gov/study/NCT07314684) | GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM | T2DM (Type 2 Diabetes Mellitus) | Phase 4 | RECRUITING | 80 |
| [NCT07415954](https://clinicaltrials.gov/study/NCT07415954) | A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | RECRUITING | 270 |
| [NCT06042153](https://clinicaltrials.gov/study/NCT06042153) | DIALYSIS-TIR Study | Type 2 Diabetes, End Stage Renal Disease on Dialysis | Phase 4 | ACTIVE_NOT_RECRUITING | 43 |
| [NCT03010475](https://clinicaltrials.gov/study/NCT03010475) | A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 41 |
| [NCT03552757](https://clinicaltrials.gov/study/NCT03552757) | Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity | Obesity, Overweight | Phase 3 | COMPLETED | 1210 |
| [NCT02243098](https://clinicaltrials.gov/study/NCT02243098) | Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects | Diabetes, Healthy | Phase 1 | COMPLETED | 31 |
| [NCT05040087](https://clinicaltrials.gov/study/NCT05040087) | Changing the Natural History of Type 2 Diabetes ("CHANGE" Study) | Type 2 Diabetes | Not phased | ACTIVE_NOT_RECRUITING | 127 |

## Common questions

**How many human trials does Semaglutide have?**
610, each listed above with a link to its original record.

**Is Semaglutide FDA approved?**
Yes — FDA-approved for type 2 diabetes and chronic weight management.

**Where does this data come from?**
ClinicalTrials.gov. We count interventional human studies only. Every trial
links to its original record.

---

*Automated aggregation from public registries. Not medical advice. No physician
has reviewed this page. Source: https://www.whatsactuallyknown.com/compounds/semaglutide*